Aviat (AVNW) Raises Revenue Guidance Range for Q2FY13

SANTA CLARA, Calif., Jan. 14, 2013 /PRNewswire/ — Aviat Networks, Inc. (NASDAQ: AVNW), the leading expert in microwave networking solutions, today updated its guidance for the second quarter of fiscal 2013. Revenues for the quarter are now expected to exceed the Company’s prior guidance range.

Updated guidance for Q2FY13

• Revenue in the range of $123M – $126M; prior guidance range was $115M – $120M
• Non-GAAP gross margin and operating expenses are expected to be consistent with prior guidance announced on November 1, 2012
• Although specific guidance for orders and cash were not previously provided, due to the timing of this press release, the Company is providing additional Q2FY13 guidance on these metrics
  • Orders greater than revenue
  • Closing cash balance of approximately $95 million

Today’s announcement is based on management’s preliminary analysis of operations for the quarter ended December 28, 2012. Aviat Networks will report complete second quarter fiscal 2013 financial results and provide guidance for the third quarter of fiscal 2013 after the market closes on January 30, 2013. Other than the information in this press release, no further financial information for Q2FY13 is planned to be provided prior to that date.

The company will host a conference call at 4:30 p.m. ET on January 30, 2013 to discuss its financial results. To listen to the live conference call, please dial 480-629-9760 or toll free at 877-941-4774, access code 4590206, by 4:20 p.m. ET. A replay also will be available starting approximately one hour after the completion of the call until February 6, 2013. To access the replay, dial 303-590-3030 or toll free at 800-406-7325, access code 4590206.

Investors are invited to listen via webcast, which will be broadcast live and via replay at http://investors.aviatnetworks.com/events.cfm.

Michael Pangia, president and CEO, and Ned Hayes, senior vice president and CFO, are presenting on January 15, 2013 at the 15^th Annual Needham & Company Growth Conference in New York City. A live webcast of the presentation will be available at 4:10 p.m. Eastern Time on January 15, 2013 and will be archived for 90 days. The webcast can be accessed from the Investor Relations page of Aviat Networks’ Web site at http://investors.aviatnetworks.com/events.cfm.

About Aviat Networks

Aviat Networks, Inc. (NASDAQ: AVNW) is a leading global provider of microwave networking solutions transforming communications networks to handle the exploding growth of IP-centric, multi-Gigabit data services. With more than 750,000 systems installed around the world, Aviat Networks provides LTE-proven microwave networking solutions to mobile operators, including some of the largest and most advanced 4G/LTE networks in the world. Public safety, utility, government and defense organizations also trust Aviat Networks’ solutions for their mission-critical applications where reliability is paramount. In conjunction with its networking solutions, Aviat Networks provides a comprehensive suite of localized professional and support services enabling customers to effectively and seamlessly migrate to next generation Carrier Ethernet/IP networks. For more than 50 years, customers have relied on Aviat Networks’ high performance and scalable solutions to help them maximize their investments and solve their most challenging network problems. Headquartered in Santa Clara, California, Aviat Networks operates in 46 countries around the world. For more information, visit www.aviatnetworks.com or connect with Aviat Networks on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

The information contained in this document includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 21E of the Securities Exchange Act and Section 27A of the Securities Act. All statements, trend analyses and other information contained herein about the markets for the services and products of Aviat Networks, Inc. and trends in revenue, as well as other statements identified by the use of forward-looking terminology, including “anticipates,” “believe,” “plan,” “estimate,” “expect,” “goal,” “will,” “see,” “continues,” “delivering,” “view,” and “intend,” or the negative of these terms or other similar expressions, constitute forward-looking statements. These forward-looking statements are based on estimates reflecting the current beliefs of the senior management of Aviat Networks. These forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. Forward-looking statements should therefore be considered in light of various important factors, including those set forth in this document. Important factors that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include the following:

• continued price erosion as a result of increased competition in the microwave transmission industry;
• the impact of the volume, timing and customer, product and geographic mix of our product orders;
• our ability to meet projected new product development dates or anticipated cost reductions of new products;
• our suppliers’ inability to perform and deliver on time as a result of their financial condition, component shortages or other supply chain constraints;
• customer acceptance of new products;
• the ability of our subcontractors to timely perform;
• continued weakness in the global economy affecting customer spending;
• retention of our key personnel;
• our ability to manage and maintain key customer relationships;
• uncertain economic conditions in the telecommunications sector combined with operator and supplier consolidation;
• the timing of our receipt of payment for products or services from our customers;
• our failure to protect our intellectual property rights or defend against intellectual property infringement claims by others;
• the effects of currency and interest rate risks; and
• the impact of political turmoil in countries where we have significant business.

For more information regarding the risks and uncertainties for our business, see “Risk Factors” in our Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on September 4, 2012 as well as other reports filed by Aviat Networks, Inc. with the SEC from time to time. Aviat Networks undertakes no obligation to update publicly any forward-looking statement for any reason, except as required by law, even as new information becomes available or other events occur in the future.

Radisys (RSYS) Increases Fourth Quarter Guidance

Radisys^® Corporation (NASDAQ: RSYS), a leading provider of embedded wireless infrastructure solutions for telecom, aerospace, defense and public safety applications, announced that, based upon preliminary results which are subject to final review and audit, it expects fourth quarter revenue near the high end of the guidance range provided on October 30, 2012 and positive non-GAAP earnings per share compared to a previous guidance range of ($0.06) to breakeven. Strong Software-Solutions revenues enabled better than expected profitability.

“A strong finish to the year in our software and solutions business along with continued operational focus enabled us to return to profitability more quickly than originally expected,” commented Brian Bronson, Radisys President and Chief Executive Officer. “Additionally, we generated positive cash flow in the fourth quarter and have adequate liquidity to retire the $16.9 million of convertible debt coming due in February 2013. We will set a specific earnings release and conference call date over the next month. I look forward to sharing the full results for the quarter, go forward guidance, and an update on the strategic objectives we outlined in October at that time.”

Non-GAAP Financial Measure

This press release contains a non-GAAP financial measure – non-GAAP earnings per share – the calculation of which excludes certain expenses, gains and losses, such as the effects of (a) purchase accounting adjustments, (b) amortization of acquired intangible assets, (c) stock-based compensation expense, (d) restructuring and acquisition-related charges (reversals), net, (e) impairment of goodwill, (f) gain on the liquidation of a foreign subsidiary, and (g) non-cash income tax expense. The Company believes that the use of non-GAAP financial measures provides useful information to investors to gain an overall understanding of its current financial performance and its prospects for the future. Specifically, the Company believes the non-GAAP results provide useful information to both management and investors by excluding certain expenses, gains and losses that the Company believes are not indicative of its core operating results. In addition, non-GAAP financial measures are used by management for budgeting and forecasting as well as subsequently measuring the Company’s performance, and the Company believes it is providing investors with financial measures that most closely align to its internal measurement processes. These non-GAAP measures are considered to be reflective of the Company’s core operating results as they more closely reflect the essential revenue-generating activities of the Company and direct operating expenses (resulting in cash expenditures) needed to perform these revenue-generating activities. The Company also believes, based on feedback provided to the Company during its earnings calls’ Q&A sessions and discussions with the investment community, that the non-GAAP financial measures it provides are necessary to allow the investment community to construct their valuation models to better align its results and projections with its competitors and market sector, as there is significant variability and unpredictability across companies with respect to certain expenses, gains and losses.

The non-GAAP financial information is presented using a consistent methodology from quarter-to-quarter and year-to-year. Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP. In addition, non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. The Company believes non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP and these measures should only be used to evaluate the Company’s results of operations in conjunction with the corresponding GAAP financial measures.

The non-GAAP financial measures disclosed by the Company should not be considered a substitute for or superior to financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.

Forward Looking Statements

This press release contains forward-looking statements, including statements about the Company’s expected results for the fourth quarter of 2012. These forward-looking statements are based on the Company’s expectations and assumptions, as of the date such statements are made, regarding the Company’s future operating performance and financial condition, the economy and other future events or circumstances. Actual results could differ materially from the outlook guidance and expectations in these forward-looking statements as a result of a number of risk factors, including, among others, (a) the Company’s dependence on certain customers and high degree of customer concentration, (b) the Company’s use of one contract manufacturer for a significant portion of the production of its products, (c) the anticipated amount and timing of revenues from design wins due to the Company’s customers’ product development time, cancellations or delays, (d) fluctuations in currency exchange rates, (e) the ability of the Company to successfully integrate the business and operations of Continuous Computing and higher than expected costs of integration, (f) the Company’s ability to successfully manage the transition from 10G to 40G ATCA product technologies, (g) performance and customer acceptance of the Trillium line of products, (h) other factors listed in the Company’s reports filed with the Securities and Exchange Commission (SEC), including those listed under “Risk Factors” in Radisys’ Annual Report on Form 10-K for the year ended December 31, 2011 and in Radisys’ subsequent Quarterly Reports on Form 10-Q, copies of which may be obtained by contacting the Company at 503-615-1100, from the Company’s investor relations web site at http://investor.radisys.com/, or at the SEC’s website at http://www.sec.gov. Although forward-looking statements help provide additional information about Radisys, investors should keep in mind that forward-looking statements are inherently less reliable than historical information. Should one or more of these risks or uncertainties materialize (or the other consequences of such a development worsen), or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. The Company believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. All information in this press release is as of January 14, 2013. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company’s expectations.

About Radisys

Radisys (NASDAQ: RSYS) is a leading provider of embedded wireless infrastructure solutions for telecom, aerospace, defense and public safety applications. Radisys’ market-leading ATCA, IP Media Server and Com Express platforms coupled with world-renowned Trillium software, services and market expertise enable customers to bring high-value products and services to market faster with lower investment and risk. Radisys solutions are used in a wide variety of 3G & 4G / LTE mobile network applications including: Radio Access Networks (RAN) solutions from femtocells to picocells and macrocells, wireless core network applications, Deep Packet Inspection (DPI) and policy management; conferencing and media services including voice, video and data, as well as customized mobile network applications that support the aerospace, defense and public safety markets.

Radisys® and Trillium® are registered trademarks of Radisys.

GlobalWise (GWIV) Launching Sales Campaign With Public Safety Market Leader Tiburon

COLUMBUS, OH — (Marketwire) — 01/14/13 — GlobalWise Investments, Inc. (OTCBB: GWIV) (OTCQB: GWIV) (www.GlobalWiseInvestments.com) and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, today announce a new sales campaign with its channel partner Tiburon (www.tiburoninc.com). This campaign, which is expected to launch this month, will target Tiburon’s client base of over 600 leading public safety agencies in North America.

Since 1980, Tiburon has set the standard of excellence for the delivery of computer aided dispatch, mobility, records management and corrections management solutions built to meet the rigorous demands of state, local and federal law enforcement, fire & rescue and corrections agencies. To support market needs and further extend the service and value provided to clients, Tiburon selected Intellinetics as its strategic partner for Enterprise Content Management. Intellinetics’ combination of advanced, mission-critical technology, public sector experience and flexible deployment models made it the best ECM partner for Tiburon.

“We are proud to be Tiburon’s ECM provider,” stated William “BJ” Santiago, CEO of GlobalWise. “As a market leader, Tiburon could choose any ECM partner. It is gratifying they selected us to fulfill a critical need within the Public Safety markets in which they serve. The Intellivue™ Total Command Electronic Document Management Solution (ITCE) is an affordable, simple to purchase and install bundle designed exclusively for Tiburon’s TotalCommand client base. With an attractive entry point of approximately $50,000, ITCE will be well received in this space. The Tiburon team has been great to work with throughout the process of integrating all the technical, sales and marketing aspects of this exciting new campaign.”

“Intellinetics has become one of our benchmark partners, setting a high standard for partner support, technology integration and hard work to deliver results,” stated Kirke Kurtis, Marketing Director for Tiburon. “The Intellivue™ platform has the unique blend of advanced privacy features, integration flexibility and ease of use that is absolutely vital to our clients. Intellinetics has been an important part of winning new clients for our company, and we are excited to bring that success into our large installed client base.”

About GlobalWise Investments, Inc.

GlobalWise Investments, Inc., via its wholly owned subsidiary Intellinetics, Inc., is a Columbus, Ohio based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file or video tape — virtually anything that can be digitized — in their enterprise from any PC, laptop, tablet or smartphone from anywhere in the world.

For additional information, please visit the Company’s corporate website: www.GlobalWiseInvestments.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

GlobalWise Investments, Inc.
Columbus, Ohio
www.GlobalWiseInvestments.com
614-388-8909
Contact@GlobalWiseInvestments.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975

Cardero (CDY) Announces Maiden Inferred Resource Estimate for Ghana Iron Project

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 01/11/13 — Cardero Resource Corp. (“Cardero” or the “Company”) (TSX:CDU)(NYSE MKT:CDY)(NYSE Amex:CDY)(FRANKFURT:CR5) announces the results of the maiden resource estimate for the Sheini Hills Iron Project, Ghana, undertaken by SRK Consulting (UK) Ltd. (“SRK”). SRK has reported an estimated inferred mineral resource of 1.3 Billion Tonnes (“Bt”), with mean grades of 33.8% Fe, 6.0% Al2O3, 37.3% SiO2 and 0.27% P, using a 15% cut-off grade, all of which falls within a Whittle optimization pit with a global strip ratio of 0.93.

Maiden Resource Estimate

SRK is preparing a National Instrument 43-101 (“NI 43-101”) technical report, including a maiden resource estimate, for the Sheini Hills Iron Project in northeast Ghana (“SRK Report”). The maiden estimated mineral resource is calculated in accordance with CIM Standards on Mineral Resources and Reserves (CIM Guidelines) as set out in NI 43-101. The effective date of the SRK Report is January 7, 2013, and the completed SRK Report will be filed on SEDAR and made available through the Company’s website within 45 days of this news release. Investors are urged to review the SRK Report in its entirety once it becomes available.

In total, SRK has reported an inferred mineral resource of 1.3 Bt, with mean grades of 33.8% Fe, 6.0% Al2O3, 37.3% SiO2 and 0.27% P (at a cutoff of 15% Fe), all of which falls within a Whittle optimisation pit which has a global strip ratio of 0.93 (waste tonnes:ore tonnes) and which was generated by SRK to restrict the estimated inferred mineral resource to material which has potential to be economically exploited.

 Table 1: Mineral Resource Statement, Sheini Hills Iron Project, Ghana, SRK
Consulting (UK) Ltd., effective date 7 January 2013. Reported above a 15% Fe
                 cut-off and within an optimized pit shell.
----------------------------------------------------------------------------
                             Resource
Zone                         Category Tonnes (Mt)  Fe %  Al2O3%  SiO2%   P %
----------------------------------------------------------------------------
Ironstone Sheini Central -
North                        Inferred       349.2  37.6     4.4   34.3  0.26
----------------------------------------------------------------------------
Ironstone Sheini Central -
Centre                       Inferred       111.1  34.6     5.2   38.0  0.28
----------------------------------------------------------------------------
Ironstone Sheini Central -
South                        Inferred       581.0  33.9     5.4   37.2  0.36
----------------------------------------------------------------------------
Ironstone Hardcap            Inferred         4.1  36.5     8.5   32.3  0.09
----------------------------------------------------------------------------
Ironstone Total              Inferred       1,045  35.2     5.1   36.3  0.32
----------------------------------------------------------------------------
Detritals                    Inferred       266.9  28.2     9.5   41.1  0.09
----------------------------------------------------------------------------
TOTAL                        Inferred       1,312  33.8     6.0   37.3  0.27
----------------------------------------------------------------------------

Notes:
(1) Mineral Resources which are not Mineral Reserves have no demonstrated
economic viability.
(2) The effective date of the Mineral Resource Estimate is 7 January 2013.
(3) The Mineral Resource Estimate for the Sheini deposit was constrained
within lithological solids and within a Lerchs-Grossman optimised pit shell
defined by the following assumptions; pig iron flow sheet; metal price of
USD400/t; slope angles of 53 degrees in the ironstone and detrital
material; a mining recovery of 95.0%; a mining dilution of 5.0%; a base case
mining cost of USD2.50/t; process operating costs of USD2.50/t ore USD4.50/t
ore in the ironstone and detrital respectively; ironstone processing
recovery of 100%; Detrital processing recovery of 25%; reductant costs of
USD0.58/t%Fe and other concentrate costs of USD33.33/t; smelting costs were
separated into power and other costs and were estimated at 27.50 USD/t and
51.00 USD/t, respectively; 90% assumed product grade.
(4) Mineral Resources for the Sheini deposit have been classified according
to the "CIM Standards on Mineral Resources and Reserves: Definitions and
Guidelines (December 2005)" by Howard Baker (MAusIMM(CP)), an independent
Qualified Person as defined in NI 43-101.

The Company cautions that the accuracy of resource and reserve estimates is, in part, a function of the quality and quantity of available data and of engineering and geological interpretation and judgment. Given the data available at the time the SRK report was prepared, the estimates presented are considered reasonable. However, they should be accepted with the understanding that additional data and analysis available subsequent to the date of the estimates may necessitate revision. These revisions may be material. SRK is unaware of any environmental, permitting, legal, title, taxation, socio-economic, marketing, and political or other relevant issues that may materially affect the mineral resources. Mineral resources which are not mineral reserves do not have demonstrated economic viability.

Mineral Resource Estimation Methodology

Resource Database

The resource database upon which the mineral resource estimate is based predominantly comprises diamond and reverse circulation drillhole data generated by Cardero from the 2012 Phase I drilling program at Sheini. This data has been supplemented by surface geological mapping and subsequent cross-sectional geological interpretations constructed on the basis of both mapping and drillhole data. The drillhole database comprises 67 diamond drillholes (9,478 metres) and 127 reverse circulation drillholes (1,923 metres). Diamond drillholes are spaced on section lines between 200 m and 800 m apart. Reverse circulation drillholes are concentrated in areas of known detrital mineralisation and are typically spaced on section lines 200 to 400 m apart. The assay database comprises 4,399 samples.

Geological Interpretation

Iron mineralization at Sheini occurs as primary ironstone (banded and granular types with local hardcap development) and as detrital iron deposits (located on plains, peripheral to the ironstone deposits). Primary iron mineralisation identified at Sheini, being classed as a “Rapitan-type iron formation”, predominantly comprises bladed haematite with lesser iron hydroxides (goethite and limonite) confined to interbedded banded iron formation and granular iron formation at the base of the Late Precambrian – Early Phanerozoic Buem Formation. The ironstone package and adjacent footwall and hanging wall lithologies have been subjected to ductile deformation resulting in a series of broadly N-S trending asymmetric inclined fold structures, offset by a series of NNE-SSW trending, and later E-W to ENE-WSW trending, brittle faults. The iron mineralisation is sedimentary in origin, and extends to a total of approximately 8.6 kilometres along strike, up to 1.2 kilometres across strike and to depths of up to 300 metres from surface.

Modelling

Geological modelling was conducted in 3D Geomodeller software, using logged ironstone as an explicit control on model geometry. Primary ironstone was modelled within three spatially distinct domains – north zone, central zone and south zone, all of which lie within the Sheini Central prospecting licence. In addition to primary ironstone mineralisation, re-deposited detrital material forms extensive flat-lying platforms adjacent to N-S trending ridges throughout the project area. Figure 1 shows the distribution of the ironstone and detrital units modelled.

To view Figure 1, please visit the following link: http://media3.marketwire.com/docs/CDU_Figure1_846080.pdf.

Classification

SRK is of the opinion that it is appropriate to classify the resource in the inferred category as defined by CIM Guidelines in this case.

Initial Metallurgical Testwork

SRK supervised and reviewed a certain amount of metallurgical test work on samples collected from the Sheini deposit so as to determine whether or not the material has potential to be used to produce a saleable product and so enable it to report the above mineral resource estimate. SRK is satisfied that the iron mineralization has reasonable prospects for economic extraction as required by CIM guidelines.

Work Completed to Date

Initial metallurgical test work has been completed by SGS Mineral Services UK Limited (“SGS”), primarily at laboratories in the UK, and by Cardero Materials Testing Laboratory Ltd. (“CMTL”), located in USA (which is owned by the Company, and is therefore not an independent testing laboratory). Petrographic reports, QEMSCAN and X-Ray Diffraction work together suggest that the iron mineralisation at Sheini consists of very finely disseminated haematite within a silica matrix. Initial work has been completed on three samples to date (Table 2).

                       Table 2: Metallurgical Samples                       

----------------------------------------------------------------------------
                                Interval Fe (%) Metallurgical   Mat Lab Head
Sample Type           Drillhole      (m)  (ALS)    Laboratory   Grade (Fe %)
----------------------------------------------------------------------------
Primary Ironstone       SCD-012     89.6   35.1           SGS           36.1
----------------------------------------------------------------------------
Detrital Iron     SCD-049 & 050     27.2    n/a           SGS           25.1
----------------------------------------------------------------------------
Primary Ironstone       SCD-048      109   36.8          CMTL           36.9
----------------------------------------------------------------------------

SGS Laboratories

SGS initially assessed a conventional gravity separation method, using a combination of gravity (heavy liquid or “HL”) separation at coarser sizes together with magnetic separation at finer sizes. For the primary ironstone, this approach was largely unsuccessful. The detrital ore exhibited a greater potential for gravitational upgrading. The HL test work was conducted at a top size of 8 mm, and individual density fractions reported assays of up to 60% Fe for the size fractions above approximately 0.5 mm. Overall, the HL test results showed the potential to produce a concentrate assaying 56.6% Fe, albeit at a low Fe recovery.

CMTL

CMTL Smelting – A raw (non-upgraded) sample with a 36.7% iron head grade was prepared and smelted in a 50kW electric arc furnace. The purpose of the smelt test was to establish if the raw samples will be amenable to smelting and production of hot metal or pig iron. The test produced a pig iron grading 91.1% iron with a 73% yield and is a successful proof of concept. These are positive results for a single smelt test on raw, unbeneficiated material. Phosphorous content returned from this test was high but the Company anticipates reduction of phosphorous can be achieved during upgrade to concentrate or via post-smelting ladle treatment.

CMTL Beneficiation Roast – CMTL used a solid-state reduction to reduce fine-grained haematite to magnetite using only a coarse grind (-4mm +1mm) prior to roasting at less than 1000 degrees C in a rotary kiln. This process was successful and the internal forces exerted by the phase transformation from haematite to magnetite induced self-liberation of the magnetite from the silica. Following conventional low intensity magnetic separation (“LIMS”) using a Davis Tube, the concentrate grade increased to 50% iron and the iron:silica ratio increased indicating that silica had been liberated and rejected.

Next Steps

Metallurgy

Cardero will continue to investigate metallurgical processes over the coming months to define improved metallurgical processing techniques. Immediate work will involve optimizing grind size and rotary kiln temperature and residence time for the beneficiation roast. It is likely that the final process will involve an initial coarse grind, reduction roast, additional grind and magnetic separation. More work will be required to prove that this technique will produce a saleable magnetite concentrate. Upgrading of the raw sample to a higher grade concentrate prior to melting would greatly enhance the potential economics of producing higher value pig iron at Sheini. Future smelting work will focus on use of beneficiated roast concentrate as feedstock to the electric arc furnace instead of raw material.

Potential Resource Expansion

Phase I drilling defined an inferred mineral resource over a strike length of approximately 9 kilometres. Airborne geophysical surveys carried out during 2012 defined anomalies over an additional strike length of approximately 24 kilometres and these anomalies were confirmed to be coincident with iron mineralization by reconnaissance mapping. Drill targets over this trend will require approximately 18,000 metres of diamond drilling to be tested. No further drilling is planned until metallurgical testing has been completed and a viable process route has been confirmed.

Qualified Person

Howard Baker B.Sc., M.Sc., MAusIMM (CP) a Principal Geologist (Mining Geology) with SRK Consulting (UK) Ltd., has acted as the Qualified Person, as defined in NI 43-101, for the SRK Report and, in particular, the resource estimate contained therein. Mr. Baker has 18 years practical experience in the mining industry, with the previous 10 years focussed on iron ore mining, exploration and mineral resource estimation. Mr. Baker worked as a Senior Mine Geologist at the BHP Billiton, Yarrie Operation in the Pilbara region of Western Australia and as a Specialist Resource Geologist for Rio Tinto Iron Ore, also in Pilbara region of Western Australia. Following this, Mr. Baker has worked a Principal Geologist for SRK on numerous iron ore deposits including those in West and Central Africa, Sweden, Finland, Canada, Portugal and Armenia. Mr. Baker has also reviewed and approved the disclosure in this news release. Both Mr. Baker and SRK are independent of the Company under NI 43-101.

ABOUT CARDERO RESOURCE CORP.

The common shares of the Company are currently listed on the Toronto Stock Exchange (symbol CDU), the NYSE-MKT (symbol CDY) and the Frankfurt Stock Exchange (symbol CR5). For further details on the Company readers are referred to the Company’s web site (www.cardero.com), Canadian regulatory filings on SEDAR at www.sedar.com and United States regulatory filings on EDGAR at www.sec.gov.

On Behalf of the Board of Directors of CARDERO RESOURCE CORP.

Michael Hunter, CEO and President

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and US securities legislation. All statements regarding the discovery and delineation of mineral deposits/resources/reserves, the potential for the expansion of the current estimated resource at Sheini, the potential for the reduction of phosphorous during upgrade to concentrate or via post-smelting ladle treatment; the potential for the economic exploitation of any of the mineral deposits at Sheini, the potential for the production of pig iron from Sheini mineralization, the potential for the Company to define improved metallurgical processing techniques, the likely makeup of the final treatment process for Sheini mineralization, the potential to be able to upgrade raw material to a higher grade concentrate; the potential for there to be a saleable concentrate or pig iron produced from Sheini mineralization; business and financing plans and business trends, are forward-looking statements. Information concerning mineral resource/reserve estimates may also be deemed to be forward-looking statements in that it reflects a prediction of the mineralization that would be encountered if a mineral deposit were developed and mined. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions, or are those, which, by their nature, refer to future events.

The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors, including, but not limited to, material changes in the assumptions underlying the maiden inferred resource estimate required as a result of changing market conditions or new data, variations in the nature, quality and quantity of any mineral deposits that may be located, variations in the market for, and pricing of, any mineral products the Company may produce or plan to produce, significant increases in any of the machinery, equipment or supplies required to develop and operate a mine at Sheini, the failure of appropriate infrastructure to be available to support the construction of a mine and the transportation of any product the Company may produce or plan to produce; a significant change in the availability or cost of the labor force required to operate a mine at Sheini, significant increases in the cost of transportation for the Company’s products, the Company’s inability to obtain any necessary permits, consents or authorizations required for its activities, the Company’s inability to produce minerals from its properties successfully or profitably, to continue its projected growth, to raise the necessary capital or to be fully able to implement its business strategies, and other risks and uncertainties disclosed in the Company’s 2012 Annual Information Form filed with certain securities commissions in Canada and the Company’s annual report on Form 40-F filed with the United States Securities and Exchange Commission (the “SEC”), and other information released by the Company and filed with the appropriate regulatory agencies. All of the Company’s Canadian public disclosure filings may be accessed via www.sedar.com and its United States public disclosure filings may be accessed via www.sec.gov, and readers are urged to review these materials, including the technical reports filed with respect to the Company’s mineral properties.

Cautionary Note Regarding References to Resources and Reserves

National Instrument 43 101 – Standards of Disclosure for Mineral Projects (“NI 43-101”) is a rule developed by the Canadian Securities Administrators which establishes standards for all public disclosure an issuer makes of scientific and technical information concerning mineral projects. Unless otherwise indicated, all resource estimates contained in or incorporated by reference in this press release have been reported in accordance with NI 43-101 and the guidelines set out in the Canadian Institute of Mining, Metallurgy and Petroleum (the “CIM”) Standards on Mineral Resource and Mineral Reserves, adopted by the CIM Council on November 14, 2004 (the “CIM Standards”) as they may be amended from time to time by the CIM.

United States shareholders are cautioned that the requirements and terminology of NI 43-101 and the CIM Standards differ significantly from the requirements and terminology of the SEC set forth in the SEC’s Industry Guide 7 (“SEC Industry Guide 7”). Accordingly, the Company’s disclosures regarding mineralization may not be comparable to similar information disclosed by companies subject to SEC Industry Guide 7. Without limiting the foregoing, while the terms “mineral resources”, “inferred mineral resources”, “indicated mineral resources” and “measured mineral resources” are recognized and required by NI 43-101 and the CIM Standards, they are not recognized by the SEC and are not permitted to be used in documents filed with the SEC by companies subject to SEC Industry Guide 7. Mineral resources which are not mineral reserves do not have demonstrated economic viability, and US investors are cautioned not to assume that all or any part of a mineral resource will ever be converted into reserves. Further, inferred resources have a great amount of uncertainty as to their existence and as to whether they can be mined legally or economically. It cannot be assumed that all or any part of the inferred resources will ever be upgraded to a higher resource category. Under Canadian rules, estimates of inferred mineral resources may not form the basis of a feasibility study or prefeasibility study, except in rare cases. The SEC normally only permits issuers to report mineralization that does not constitute SEC Industry Guide 7 compliant “reserves” as in-place tonnage and grade without reference to unit amounts. In addition, the NI 43-101 and CIM Standards definition of a “reserve” differs from the definition in SEC Industry Guide 7. In SEC Industry Guide 7, a mineral reserve is defined as a part of a mineral deposit which could be economically and legally extracted or produced at the time the mineral reserve determination is made, and a “final” or “bankable” feasibility study is required to report reserves, the three-year historical price is used in any reserve or cash flow analysis of designated reserves and the primary environmental analysis or report must be filed with the appropriate governmental authority.

This press release is not, and is not to be construed in any way as, an offer to buy or sell securities in the United States.

NR02-13

Contacts:
Cardero Resource Corp.
Andrew Muir
Direct Tel: 604 638-3287

General Contact:
Cardero Resource Corp.
604 408-7488 or Toll Free: 1-888-770-7488
604 408-7499 (FAX)
info@cardero.com

Radisys (RSYS) to Present at the Needham Growth Conference

Radisys^® Corporation (NASDAQ: RSYS), a leading provider of embedded wireless infrastructure solutions for telecom, aerospace, defense and public safety applications, announced that it will participate in the 2013 Needham Growth Conference on January 15, 2013 in New York, NY. Brian Bronson, Radisys’ President and Chief Executive Officer, will present an overview of the Company’s business and strategy on Tuesday January 15, 2013 at 2:10 p.m. ET. Mr. Bronson’s presentation will be available on the Company’s investor relations website at http://investor.radisys.com on Monday January 14, 2013.

About Radisys

Radisys (NASDAQ: RSYS) is a leading provider of embedded wireless infrastructure solutions for telecom, aerospace, defense and public safety applications. Radisys’ market-leading ATCA, IP Media Server and Com Express platforms coupled with world-renowned Trillium software, services and market expertise enable customers to bring high-value products and services to market faster with lower investment and risk. Radisys solutions are used in a wide variety of 3G & 4G / LTE mobile network applications including: Radio Access Networks (RAN) solutions from femtocells to picocells and macrocells, wireless core network applications, Deep Packet Inspection (DPI) and policy management; conferencing and media services including voice, video and data, as well as customized mobile network applications that support the aerospace, defense and public safety markets.

Radisys® and Trillium® are registered trademarks of Radisys.

(EDMC) Announces Fiscal 2013 Second Quarter Earnings Conference Call

PITTSBURGH, Jan. 11, 2013 /PRNewswire/ — Education Management Corporation (NASDAQ:EDMC), a leading provider of post-secondary education, announced today that it will host a conference call at 9:00 a.m. Eastern Time on Thursday, January 31, 2013 to review financial results for the second quarter of fiscal 2013. Results for the quarter are expected to be released after the market close on Wednesday, January 30, 2013.

Interested parties can access the live webcast of the conference call at www.edmc.edu. Participants can also listen to the conference call by dialing 412-317-6789. Please log-in or dial-in at least 10 minutes prior to the start time to ensure a connection.

A replay of the conference call will be available by dialing 877-344-7529 and providing the access code of 451200. The replay will begin at approximately 11:00 a.m. Eastern Time on Thursday, January 31, 2013 and end at 9:00 a.m. Eastern Time on February 15, 2013. An archive of the webcast will be available for one year on the Investor Relations section of the Education Management website (www.edmc.edu).

About Education Management

Education Management (www.edmc.edu), with approximately 132,000 students as of October 2012, is among the largest providers of post-secondary education in North America, based on student enrollment and revenue, with a total of 110 locations in 32 U.S. states and Canada.  We offer academic programs to our students through campus-based and online instruction, or through a combination of both. We are committed to offering quality academic programs and continuously strive to improve the learning experience for our students.  Our educational institutions offer students the opportunity to earn undergraduate and graduate degrees and certain specialized non-degree diplomas in a broad range of disciplines, including design, media arts, health sciences, psychology and behavioral sciences, culinary, fashion, business, education, legal and information technology.

This press release may include information that could constitute forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements may involve risk and uncertainties that could cause actual results to differ materially from any future results encompassed within the forward-looking statements. Factors that could cause or contribute to such differences include those matters disclosed in the Company’s Securities and Exchange Commission filings. Past results of Education Management are not necessarily indicative of its future results. Education Management does not undertake any obligation to update any forward-looking statements.

EnerNOC (ENOC) CEO Tim Healy to Speak at 15th Annual Needham Growth Conference

BOSTON, Jan. 11, 2013 (GLOBE NEWSWIRE) — EnerNOC, Inc. (Nasdaq:ENOC), a leading provider of energy management applications and services for the smart grid, today announced that its Chairman and Chief Executive Officer, Tim Healy, will present at the 15^th Annual Needham Growth Conference on Wednesday, January 16, 2013, at 1:30pm EDT at The New York Palace Hotel in New York City.

A live audio webcast of the presentation will be accessible under “Investor Events” on the Investors page of the Company’s website at investor.enernoc.com, and a replay will be available one hour after the event concludes on January 16 and will be archived for 90 days.

EnerNOC’s webcast link is: http://wsw.com/webcast/needham55/enoc/

About EnerNOC

EnerNOC unlocks the full value of energy management for our utility and commercial, institutional, and industrial (C&I) customers by delivering a comprehensive suite of demand-side management services that reduce real-time demand for electricity, increase energy efficiency, improve energy supply transparency in competitive markets, and mitigate emissions. EnerNOC’s Utility Solutions™ offerings, which include both Implementation and Consulting services, are helping hundreds of utilities and grid operators worldwide meet their demand-side management objectives. EnerNOC serves thousands of commercial, institutional, and industrial customers worldwide through its suite of energy management applications including: DemandSMART™, comprehensive demand response; EfficiencySMART™, continuous energy savings; and SupplySMART™, energy price and risk management. Our Network Operations Center (NOC) offers 24x7x365 customer support. For more information, visit www.enernoc.com.

The EnerNOC, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5804

CONTACT: Media Relations:
         Sarah McAuley
         (617) 532.8195
         news@enernoc.com

         Investor Relations:
         Jennifer Varley
         (617) 532.8104
         ir@enernoc.com

Hurco (HURC) Reports Fourth Quarter and Full-Year Results

INDIANAPOLIS, Jan. 11, 2013 (GLOBE NEWSWIRE) — Hurco Companies, Inc., (Nasdaq:HURC) today reported results for the fourth quarter and the fiscal year ended October 31, 2012. For the fourth quarter of fiscal 2012, Hurco recorded net income of $4,086,000, or $0.63 per diluted share, as compared to net income of $2,654,000, or $0.41 per diluted share, for the corresponding period in fiscal 2011. For the full fiscal year 2012, Hurco recorded net income of $15,638,000, or $2.40 per diluted share, as compared to net income of $11,124,000, or $1.71 per diluted share, for fiscal 2011.

Sales and service fees for the fourth quarter of fiscal 2012 were $56,067,000, an increase of $7,496,000, or 15%, from the prior year period. This quarter-over-quarter improvement is net of the adverse impact of $2,087,000, or 4%, in the fourth quarter of fiscal 2012, due to a weaker Euro when translating foreign sales to U.S. Dollars for financial reporting purposes. Sales and service fees for the full fiscal year totaled $203,117,000, an increase of $22,716,000, or 13%, from fiscal 2011. The unfavorable impact of currency translation on the full fiscal year-over-year comparison was $7,609,000, or 4%.

The following table sets forth net sales and service fees by geographic region for the quarter and fiscal year ending October 31, 2012 and 2011 (in thousands), respectively:

The fourth quarter increase in sales was driven by increased demand in North America and Europe. The 8% increase in Europe was actually 15% when adjusted to exclude the negative impact of foreign currency translation due to a weaker Euro. Compared to the fourth quarter of fiscal 2011, unit shipments for the fourth quarter of fiscal 2012 increased in North America by 33%, in Europe by 13%, and in Asia Pacific by 12%. For the full fiscal year, sales increased in all regions, driven by higher customer demand. Unit shipments for the full year 2012, compared to fiscal 2011, increased in North America by 14%, in Europe by 4% and in Asia Pacific by 16%.

The following table sets forth new orders booked by geographic region for the fourth quarter and fiscal year ending October 31, 2012 and 2011 (in thousands), respectively:

During the fourth quarter of 2012, orders increased in North America and Europe due to favorable market conditions. We experienced increased orders in North America, following our successful showing at the International Manufacturing Technology Show (IMTS) in Chicago where we launched our rebranding initiative and new line of high speed machines. We experienced a decline in order activity in Asia where industrial activity has been slowing. Compared to the fourth quarter of fiscal 2011, unit orders for the fourth quarter of fiscal 2012 increased in North America by 54% and in Europe by 22%, but decreased in Asia Pacific by 9%. During the full fiscal year 2012, orders remained relatively consistent with the prior fiscal year. Unit orders for the fiscal year 2012 compared to fiscal 2011 increased in North America by 22%, but decreased in Europe by 9% and in Asia Pacific by 22%. The impact of currency translation on orders booked in the fourth quarter and full fiscal year was consistent with the impact on sales.

Hurco’s fourth quarter gross profit was $17,220,000, or 31% of sales, compared to $15,682,000, or 32% of sales, for the prior year period. For the full fiscal year 2012, gross profit was $63,181,000, or 31% of sales, compared to $55,874,000, or 31% of sales, for fiscal 2011. The increase in gross profit for the fourth quarter and the year was due primarily to the increase in sales.

Selling, general and administrative expenses for the fourth quarter of fiscal 2012 were $11,870,000, an increase of $778,000, or 7%, from the corresponding period in 2011.  Selling, general and administrative expenses were $41,160,000 for fiscal 2012, an increase of $2,667,000, or 7%, over fiscal 2011. The increases in selling, general and administrative expenses for the fourth quarter and fiscal year were primarily due to higher sales and marketing expenses and higher commissions as a result of increased sales.

Other expenses during the fourth quarter of fiscal 2012 decreased $1,051,000 compared to the fourth quarter of fiscal 2011. Other expenses for fiscal 2012 decreased by $1,605,000. These decreases were primarily due to decreased foreign currency losses experienced in fiscal 2012.

Cash and cash equivalents totaled $35,770,000 as of October 31, 2012, compared to $44,961,000 as of October 31, 2011. Inventories as of October 31, 2012 were $91,320,000, an increase of $10,193,000, or 13%, from the end of the prior fiscal year primarily due to an increase in finished goods inventory intended to meet forecasted growth in customer demand. Working capital, excluding cash, was $88,239,000 as of October 31, 2012, compared to $61,885,000 as of October 31, 2011. The increase in working capital, excluding cash, was primarily due to increased inventory resulting from higher production levels and increased accounts receivable from higher sales volumes.

Michael Doar, President and Chief Executive Officer, stated, “Considering the economic uncertainty in Europe, we finished the year with a strong performance. I believe our results are a testament to customer acceptance of our cutting edge control technology and product line expansion. North America achieved record sales for the quarter, which I attribute to the excitement surrounding the rebranding initiative that we introduced at the International Manufacturing Technology Show in Chicago. Additionally, I believe U.S. customers appreciate the fact that our control technology focuses on helping them increase profitability, especially in the manufacture of small-to-medium-sized lots, which accounts for the majority of their machining activity. Going forward, we will continue to deliver machine tools with advanced technology that simplifies complex operations, while providing a user interface that is intuitive and user-friendly.”

Hurco Companies, Inc. is an industrial technology company that designs and produces interactive computer controls, software and computerized machine tools for the worldwide metal cutting and metal forming industry. The end market for the Company’s products consists primarily of independent job shops and short-run manufacturing operations within large corporations in industries such as aerospace, defense, medical equipment, energy, transportation and computer equipment. The Company is based in Indianapolis, Indiana, with manufacturing operations in Taiwan and China, and sells its products through direct and indirect sales forces throughout North America, Europe, and Asia. The Company has sales, application engineering support and service subsidiaries in China, England, France, Germany, India, Italy, Poland, Singapore, South Africa and the United States of America.  Web Site: www.hurco.com

The Hurco Companies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14761

This news release contains forward looking statements which involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These factors include, among others, the cyclical nature of the machine tool industry, changes in general economic and business conditions that affect demand for our products, the risks of our international operations, changes in manufacturing markets, innovations by competitors, the ability to protect our intellectual property, fluctuations in foreign currency exchange rates, increases in prices of raw materials, quality and delivery performance by our vendors, changes in operations due to acquisitions, the loss of key personnel, and governmental actions and initiatives including import and export restrictions and tariffs.

CONTACT: John G. Oblazney
         Vice President & Chief Financial Officer
         317-293-5309

Kingold (KGJI) Announces Sale of Common Stock to China-based Investors for $12.6 Million

WUHAN, China, Jan. 11, 2013 /PRNewswire/ — Kingold Jewelry, Inc. (NASDAQ: KGJI), (“Kingold” or the “Company”), one of China’s leading manufacturers and designers of high quality 24-karat gold jewelry, ornaments and investment-oriented products, today announced that the Company has entered into a Subscription Agreement (“Agreement”) with three individuals providing for the sale of 7,000,000 shares of its common stock at a price of $1.80 per share for gross proceeds of $12,600,000.

The Company also issued to the investors, on a pro rata basis, warrants to purchase up to an additional 2,800,000 shares of its common stock at an exercise price of $1.80, which warrant is not cashless exercise but is exercisable at any time in whole or in part for twelve months following the date of the Agreement.  The Company intends to use the proceeds from this transaction to purchase additional raw materials for its products, working capital and other general corporate purposes.

Mr. Zhihong Jia, Chairman and CEO of Kingold Jewelry, Inc. stated, “We were pleased to reach an agreement that will allow our Company to accelerate its growth. While the terms were at a significant discount to the Company’s book value, the shares sold at a purchase price higher than our closing price. The principle investors in this transaction have followed Kingold prior to its initial public offering and have held a long-standing belief in the Company’s fundamentals and prospects in China’s gold market. We look forward to keeping investors apprised of our progress in the coming weeks.”

About Kingold Jewelry, Inc.
Kingold Jewelry, Inc. (NASDAQ: KGJI), centrally located in Wuhan City, China’s fourth largest city, was founded in 2002 and today is one of China’s leading designers and manufacturers of 24-karat gold jewelry, ornaments and investment-oriented products. The Company sells both directly to retailers as well as through major distributors across China. Kingold has received numerous industry awards and has been a member of the Shanghai Gold Exchange since 2003. For more information, please visit www.kingoldjewelry.com.

Business Risks and Forward-Looking Statements
This press release contains forward-looking statements that are subject to the safe harbors created under the Securities Act of 1933 and the Securities Exchange Act of 1934. Readers are cautioned that actual results could differ materially from those expressed in any forward-looking statements. In addition, please refer to the risk factors contained in Kingold’s SEC filings available at www.sec.gov, including Kingold’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. Kingold undertakes no obligation to update or revise any forward-looking statements for any reason.

Company Contact
Kingold Jewelry, Inc.
Bin Liu, CFO
+1-847-660-3498 (US) / +86-27-6569-4977 (China)
bl@kingoldjewelry.com

INVESTOR RELATIONS
The Equity Group Inc.
Adam Prior, Vice President
(212) 836-9606
aprior@equityny.com

Katherine Yao, Account Associate
+86 10-6587-6435
kyao@equityny.com

Chuy’s (CHUY) Announces Preliminary Fourth Quarter 2012 Sales Results

AUSTIN, Texas, Jan. 10, 2013 (GLOBE NEWSWIRE) — In advance of its presentation next week at the ICR XChange Investor Conference, Chuy’s Holdings, Inc. (the “Company”) (Nasdaq:CHUY) today announced preliminary, unaudited revenues and comparable restaurant sales results for its fourth quarter ended December 30, 2012. The Company also provided updated guidance for fiscal year 2012, as well as an initial outlook for fiscal year 2013.

For the fourth quarter of 2012, total revenues were approximately $46.7 million, an increase of 40.3% compared to revenues of $33.3 million in the fourth quarter of 2011. The Company’s fourth quarter of 2012 included 14 weeks compared to 13 weeks in the fourth quarter of 2011. Revenues in the fourth quarter of 2012 attributed to the extra week totaled approximately $3.3 million.

The Company’s comparable restaurant sales increased 5.2% during the quarter for the 13-week period ended December 23, 2012 compared to the 13-week period ended December 25, 2011. Comparable restaurant sales were positively impacted by an extra 1.5 operating days in 2012 as a result of the Company’s restaurant closing schedule on Christmas Eve and Christmas Day during the 13-week period in 2011. Excluding the impact of the extra 1.5 days, comparable restaurant sales increased 3.0%.

Based upon these preliminary sales results, the Company has updated its guidance and currently anticipates that its fiscal year 2012 pro forma diluted net income per share will range between $0.59 to $0.61. The Company’s 2012 guidance includes an estimated $0.04 to $0.05 per share positive impact due to the extra week in the fourth quarter of 2012, an increase from the Company’s previous expectation of $0.02 to $0.03, due to better than expected sales in the 53^rd week.

Steve Hislop, President and Chief Executive Officer of Chuy’s Holdings, Inc., stated, “We’re pleased to cap off fiscal 2012 with solid sales growth driven by strong comparable restaurant sales and continued contribution from our new unit openings. With a strong pipeline of new units planned for 2013, we are confident that we are in great shape to build upon our 2012 results as we enter the new year.”

Preliminary results remain subject to the completion of normal quarter-end accounting procedures and adjustments and are subject to change. The Company expects to release financial and operating results for its fourth quarter and year ended December 30, 2012 during the last two weeks in February.

2013 Outlook

The Company anticipates that its fiscal year 2013 diluted net income per share will range from $0.66 to $0.69. This range is based, in part, on the following assumptions:

• Comparable restaurant sales growth between 1.0% and 1.5%;
• The opening of eight to nine new restaurants; and
• Weighted average pro forma diluted shares outstanding of 16.7 million to 16.8 million shares.

On a comparable calendar week basis, the Company expects its reported first quarter comparable sales growth percentage to be consistent with its annual guidance. However, due to the 53rd week in fiscal 2012, there is a one-week calendar shift in the comparison of the fiscal first quarter of 2013 compared to the fiscal first quarter of 2012. As a result of this shift, the week between Christmas and New Year’s, traditionally a high volume week for the Company’s restaurants, will be replaced with an average volume week in the first quarter 2013. The Company expects this shift to reduce revenues by approximately $700,000 to $800,000 and impact diluted net income per share by approximately $0.01 to $0.02 during the first quarter of 2013.

The Company will provide additional information regarding its fiscal year 2013 outlook when it releases fourth quarter 2012 earnings.

15^th Annual ICR XChange Investor Conference Participation

The Company will present at the 15th Annual ICR XChange Investor Conference on Wednesday, January 16, 2013 at the Fontainebleau Miami Beach Hotel in Florida. The presentation will begin at 3:40 p.m. Eastern Time and will be webcast live. To access the presentation, please visit www.chuys.com under the tab “Investor Relations” or directly through the ICR XChange website at www.icrxchange.com.

About Chuy’s

Founded in Austin, Texas in 1982, Chuy’s owns and operates 39 full-service restaurants across eight states serving a distinct menu of authentic, made from scratch Tex Mex inspired dishes. Chuy’s highly flavorful and freshly prepared fare is served in a fun, eclectic and irreverent atmosphere, while each location offers a unique, “unchained” look and feel, as expressed by the concept’s motto “If you’ve seen one Chuy’s, you’ve seen one Chuy’s!”. For further information about Chuy’s, including our newest locations, please visit Chuys.com. For the nearest location or a complete menu, visit the Chuy’s website at www.chuys.com.

Definitions and Non-GAAP Measures

Comparable restaurant sales reflect changes in sales for the comparable group of restaurants over a specified period of time. We consider a restaurant to be comparable in the first full quarter following the 18th month of operations. Changes in comparable sales reflect changes in customer count trends as well as changes in average check.

We prepare our financial statements in accordance with generally accepted accounting principles (GAAP). Within this press release, we make reference to our expectations for non-GAAP pro forma net income. Pro forma net income represents our net income plus the sum of the net reduction in our interest expense and the application of the net proceeds of the IPO to repay $79.4 million of the Company’s debt, the elimination of our management fees and expenses as a result of our IPO, other non-recurring charges less the incremental costs of being a public company and the pro forma incremental income tax expense resulting from the aforementioned adjustments and to adjust the effective rate to the long-term estimated effective rate of 30%.

Forward-Looking Statements

Statements in this release that are not historical facts, including, without limitation, those relating to our anticipated financial performance, are forward-looking statements that involve risks and uncertainties. Such statements are based upon the current beliefs and expectations of the management of the Company. Actual results may vary materially from those contained in forward-looking statements based on a number of factors including, without limitation, the actual number of restaurant openings, the sales at the Company’s restaurants, changes in restaurant development or operating costs, such as food and labor, the Company’s ability to leverage its existing management and infrastructure, changes in restaurant pre-opening expense, general and administrative expenses, capital expenditures, or the Company’s effective tax rate, changes in the number of diluted share outstanding, strength of consumer spending, conditions beyond the Company’s control such as weather, natural disasters, disease outbreaks, epidemics or pandemics impacting the Company’s customers or food supplies, acts of war or terrorism and other factors disclosed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission. Investors should take such risks into account when making investment decisions. Stockholders and other readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The Company undertakes no obligation to update any forward-looking statements except as required by law.

CONTACT: Investor Relations Contact:
         Fitzhugh Taylor
         203-682-8261
         investors@chuys.com

Oculus (OCLS) Announces Plan to Spin Off Biotechnology Business

Oculus Management Conference Call Begins at 4:30 p.m. (ET) Today

PETALUMA, Calif., Jan. 10, 2013 (GLOBE NEWSWIRE) — Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) today announced that its board of directors has unanimously approved a spin-off of its novel biotechnology business, Ruthigen, Inc.

Oculus management is currently working with securities counsel and bankers on a plan to provide equity in Ruthigen to Oculus shareholders. Oculus expects the spinoff to be a tax-free stock distribution and ultimately anticipates Ruthigen to become an independent NASDAQ-traded company. Oculus has retained bankers and financial advisors for the spinoff, and expects the spinoff to be completed in 2013. Execution of the transaction requires further work relative to structure, governance and other significant matters and risks.

Upon completion of the spinoff, Hoji Alimi, founder and current chief executive officer of Oculus, will remain on the board of directors at Oculus and serve as chairman and chief executive officer of Ruthigen, Inc. Jim Schutz, the current chief operating officer and director of Oculus, will assume the role of chief executive officer of Oculus, with a new board chair to be elected shortly. Each company will operate with independent management teams and boards of directors to establish separate governance and financials as required by accounting rules. Additional details regarding structure will be determined and disclosed at a later time.

Oculus will retain all Microcyn drug and device indications while Ruthigen will focus on RUT58-60, a drug candidate intended for the prevention of infection in trauma and surgical procedures.  RUT58-60 is a new unique chemical formulation containing twice the concentration of hypochlorous acid, along with magnesium and no sodium hypochlorite.

Alimi said: “By separating these unique businesses into two companies, we believe each company will benefit from greater strategic and managerial focus and be better positioned to capitalize on future market opportunities. Under the plan currently under consideration, Oculus shareholders will receive shares of Ruthigen. Ultimately, we are seeking to create additional value for current and future shareholders of both Oculus and Ruthigen.

“Our Microcyn business will continue as it has over the past seven years providing life saving products for patients without the additional burden of drug development costs. Oculus has a foundation of strong fundamentals, including sustainable revenues from several key markets and a solid plan for new sources of revenue growth over the next several years.”

Oculus’ intent is to secure additional FDA and CE regulatory approvals and to expand medical device offerings over the next 12 months. This will provide current partners with new products and a growing platform of products for new partners.  While Oculus will continue promoting Microcyn-based products for topical use, Ruthigen intends to focus on use of its uniquely differentiated drug for internal use targeting organ exposure. Ruthigen intends to identify a partner for its European drug indication as well as file an S-1 registration statement to fund its pivotal drug program in the United States. Upon completion of a public offering, the entities will operate as independent entities.

“The spin-off of Ruthigen should be attractive to shareholders who are interested in companies that are addressing the critical issue of surgical infection,” said Alimi. “Initially, we intend to leverage our previous phase two drug data for use in regulatory approvals relative to the prevention of infection in surgeries.”

The completion of the proposed spinoff is subject to certain customary conditions, including final approval by Oculus’ board of directors, the filing and effectiveness of appropriate filings with the U.S. Securities and Exchange Commission including a registration statement on form S-1, and any necessary third-party consents, as well as certain other matters relating to the spinoff, receipt of legal opinions, execution of intercompany agreements, and final approval of the transactions contemplated by the spinoff, as may be required under Delaware law. Oculus notes that there can be no assurance that any separation transaction will ultimately occur, or, if one does occur, its terms or timing.

Management Conference Call

Oculus management will hold a conference call today to discuss the spin-off and to answer questions, beginning at 4:30 p.m. ET. Individuals interested in participating in the conference call may do so by dialing (877) 303-7607 for domestic callers or (973) 638-3203 for international callers. Those interested in listening to the conference call live via the Internet may do so at http://ir.oculusis.com/events.cfm. Log on approximately 30 minutes prior to the presentation in order to register and download the appropriate software. Please note that those listening via the web do not have the ability to pose questions.

A telephone replay will be available for seven days following the conclusion of the call by dialing (855) 859-2056 for domestic callers, or (404) 537-3406 for international callers, and entering conference code 87524998. A webcast replay will be available on the site at http://ir.oculusis.com/events.cfm for one year following the call.

About Oculus Innovative Sciences

Oculus Innovative Sciences is a healthcare company that designs, produces and markets innovative, safe and effective anti-infective products and medical devices while also developing multiple drug candidates for various indications including treatment of acne and surgical suite use. Oculus is pioneering innovative solutions in multiple markets for the dermatology, surgical, wound care, and animal healthcare markets, and has commercialized products in the United States, Europe, India, China, Mexico and select Middle East countries. The company’s headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. More information can be found at www.oculusis.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the Company’s commercial and technology progress and future financial performance. These forward-looking statements are identified by the use of words such as “provide,” “execution,” “assume,” and “intended,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, the uncertainties associated with effecting a spinoff of a separate public company, and the discretion of Oculus’ Board of Directors to delay or cancel the spinoff prior to execution, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including the annual report on Form 10-K for the year ended March 31, 2012. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements except as required by law.

Oculus press releases contain information about products, which may or may not be available in any particular country, and if applicable, may have received approval or market clearance by a governmental regulatory body for different indications and restrictions in different countries. Each country has specific laws, regulations and medical practices governing the communication of medical or other information about medical products. Nothing herein should be construed as a solicitation or promotion for any product or for an indication for any product, which is not authorized by the laws and regulations of the country where the reader resides.

Oculus and Microcyn Technology are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.

CONTACT: Media and Investor Contact:
         Oculus Innovative Sciences, Inc.
         Dan McFadden
         Director of Public and Investor Relations
         (425) 753-2105

Pro-Dex (PDEX) Announces Fiscal Second Quarter And Six-Month Results

IRVINE, Calif., Jan. 10, 2013 /PRNewswire/ — PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal second quarter and six months ended December 31, 2012.

Quarter Ended December 31, 2012

Sales for the quarter ended December 31, 2012 decreased 25% to $3.0 million from $4.0 million for the corresponding quarter in 2011.  As the Company has previously discussed, this decrease was primarily the result of reductions in purchases of the Company’s powered surgical instrument products by its former largest customer, partially offset by increases in such surgical instrument sales to other customers.  Excluding sales to the Company’s former largest customer, which represented a reduction of $1.5 million in the quarter ended December 31, 2012 from the corresponding quarter in 2011, sales increased $524,000, or 25%, in the quarter ended December 31, 2012.

Gross profit for the quarter ended December 31, 2012 was $1.0 million, or 34%, compared to gross profit of $1.2 million, or 31%, for the year-ago period.  The increase in gross profit as a percentage of sales from 2011 to 2012 was due primarily to a reduction in warranty costs and improvements in manufacturing efficiencies, partially offset by unfavorable changes in product mix.

Operating expenses, which include selling, general and administrative, and research and development expenses, for the quarter ended December 31, 2012 decreased 10% to $1.4 million from $1.6 million in the prior year’s corresponding quarter.  This decrease was attributable to the effects of reduced employee compensation, other operating expense cuts, and the utilization of engineering resources in contractual revenue-producing activities. Included in operating expenses for the quarter ended December 31, 2012 was $42,000 of legal and other costs associated with the contested election of directors, without which such costs the reduction in operating expenses would have been 12%.

Loss from continuing operations for the quarter ended December 31, 2012 was $364,000, compared to a loss from continuing operations of $329,000 in the corresponding quarter in 2011.  Net loss for the quarter ended December 31, 2012 was $348,000, or $0.11 per diluted share, compared to a net loss of $292,000, or $0.09 per diluted share, for the corresponding quarter in 2011.  Earnings before interest, income taxes and depreciation (“EBITDA”) for the quarter ended December 31, 2012 was a loss of $196,000, compared to a loss of $130,000 in the corresponding quarter in 2011.

During the quarter ended December 31, 2012, the Company used $619,000 of cash in operating activities.  This use of cash reflects primarily payments made in the second fiscal quarter for the build-up of inventory in first fiscal quarter in anticipation of customer orders and pursuant to the Company’s operating plan, one of the foundational objectives of which is to reduce production lead times.

Six Months Ended December 31, 2012

Sales for the six months ended December 31, 2012 decreased 29% to $6.5 million from $9.1 million in the corresponding six-month period in 2011.  Excluding sales to the Company’s former largest customer, which represented a reduction of $3.8 million in the six months ended December 31, 2012 from the corresponding period in 2011, sales for the six months ended December 31, 2012 increased $1.2 million, or 25%, in the six months ended December 31, 2012. During the six months ended December 31, 2012, the Company received new orders of $9.4 million, compared to $2.8 million in the corresponding period in 2011, excluding orders received from the former largest customer.  The book to bill ratio for the six months ended December 31, 2012 was 1.5.

For the six months ended December 31, 2012, gross profit was $2.3 million, or 35%, compared to $3.4 million and 37%, respectively, for the corresponding period in 2011. The decrease in gross profit as a percentage of sales from 2011 to 2012 resulted primarily from reduced manufacturing efficiencies and unfavorable changes in product mix, partially offset by a reduction in warranty costs.

Operating expenses for the six months ended December 31, 2012 decreased 19% to $2.7 million, from $3.3 million in the corresponding six-month period of 2011. This decrease was attributable to the effects of reduced employee compensation, other operating expense cuts, and the utilization of engineering resources in contractual revenue-producing activities.

For the six months ended December 31, 2012, loss from continuing operations was $418,000, compared to income from continuing operations of $17,000 for the corresponding period in 2011.  Net loss for the 2012 six-month period was $365,000, or $0.11 per diluted share, as compared to net income of $154,000, or $0.05 per diluted share, for the corresponding period in 2011.  EBITDA for the six months ended December 31, 2012 was a loss of $55,000, compared to income of $473,000 in the corresponding period one year ago.

During the six months ended December 31, 2012, the Company used $791,000 of cash in operating activities.  This use of cash reflects primarily the previously mentioned build-up of inventory in first fiscal quarter.  In addition, as announced previously, in September 2012 the Company repaid the entire outstanding balance on the term loan from Union Bank amounting to $685,000.  As a result of the foregoing, cash on hand at December 31, 2012 was $2.5 million, compared to $4.1 million at June 30, 2012.

Michael J. Berthelot, the Company’s President and Chief Executive Officer, commented, “We believe that the results of the quarter and six months ended December 31, 2012 reflect continued progress on our strategy to move our company forward.  We believe that our continuing efforts to attract, quote on and win new business are showing results.  In the six months ended December 31, 2011, the first half of fiscal year 2012, we submitted five proposals to potential customers, and submitted eight proposals for the entire fiscal year.  So far in this current fiscal year we have already submitted eight proposals in the six months ended December 31, 2012 and have won one of them.  As important, the value of the current year proposals in both non-recurring engineering and production value materially exceed those from last year.  While we can offer no assurances that we will win any of the business upon which we have quoted, we know that we cannot win any business on which we do not quote.  We continue to win business from new customers as well as current customers, as shown in a 25% increase in sales of powered surgical instruments to customers other than our former largest customer compared to last year’s corresponding quarter and six-months, and continue to build our backlog with a book to bill ratio of 1.5 for both the quarter and the six months ended December 31, 2012.”

“Our continuing efforts at cost reduction and improved manufacturing efficiencies led to our gross margin for the quarter ended December 31, 2012 increasing to 34% from 31% in last year’s corresponding quarter in spite of a 25% reduction in sales volume and an unfavorable shift in product mix,” said Mr. Berthelot.  “Our programs to reduce cost in every non-manufacturing department continue to bear fruit, as evidenced by the 10% reduction in operating costs for the quarter from last year.  It is important to point out that $42,000 of the general and administrative costs for the quarter are associated with the contested election of directors that we would not normally incur.”

Mr. Berthelot said, “With respect to product innovation and quality improvement, much of the new proposals discussed above revolve around our Pro-Driver platform and involve various derivatives and modifications to our basic product. While the time-consuming process from initial meeting to proposal, development, testing, acceptance and production may run from twelve to eighteen months and involve resources from sales and marketing, engineering, quality assurance, operations and finance, we have achieved success in winning customer acceptance of our development process and we hope that success will continue on if and when the product is released to production.  We have been working on an expansion of our dental product line for several months.  With a resurgent marketing effort, we hope to launch a new product that will fill out our dental product line during the next six months. As we push forward our product innovation and development efforts and move to protect our intellectual property, we are seeing greater spending on legal fees associated with patent and trademark filings, which aggregated $22,000 and $47,000 during the quarter and six months ended December 31, 2012, respectively.”

Mr. Berthelot continued, “Lead times for our most significant products continue to improve.  As a result of a change in our production and planning processes, we are now able to ship our standard Pro-Drivers, the product which is currently attracting the most interest from potential customers, within two days of order for small volumes and two weeks for larger volumes, compared to quoted lead times of sixteen weeks in last fiscal year’s fourth quarter.  We believe that an improved responsiveness to customer requests for samples and small volume test and evaluation lots will help us in our efforts to participate from the early phases of new customer programs.”

“While we are making progress, we still have much to do.  The second quarter was, we believe, the toughest of the fiscal year, partly due to our shutdown of operations for two weeks during the quarter for the Thanksgiving, Christmas and New Year holidays as part of our cost reduction program.  Our backlog is strong for the second half of fiscal 2013.  We expect to continue to press down on our cost structure while increasing engineering resources.  We expect the programs and projects that we have begun to move our company forward and to build value for every shareholder.”

“Of course,” Mr. Berthelot noted, “we appreciate the support of each and every shareholder as we pursue our strategy amidst the distraction and diversion of resources due to the contested election of directors.  We understand that there have been some logistical problems in our proxy materials arriving to our shareholders on the West Coast.  If you have not yet received the Company’s proxy materials which include the BLUE proxy card, we encourage you to contact our proxy solicitor, AST Phoenix Advisers, at 1-866-721-1318 and ask for the materials to be sent to you.  We ask that all of our shareholders vote for the Pro-Dex director nominees using the BLUE proxy card as quickly as possible, and we thank you for your support.”

Teleconference Information:

Investors and analysts are invited to listen to a broadcast review of the Company’s fiscal 2013 second quarter and six-month financial results today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) that may be accessed by visiting the Company’s website at www.pro-dex.com.  The conference call may also be accessed at www.InvestorCalendar.com. Investors and analysts who would like to participate in the conference call may do so via telephone at (877) 407-8033, or at (201) 689-8033 if calling from outside the U.S. or Canada.

For those who cannot access the live broadcast, a replay will be available approximately two hours after the completion of the call until midnight (Eastern Time) on January 24, 2013 by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 407053.  An online archive of the broadcast will be available on the Company’s website www.pro-dex.com for a period of 365 days.

About Pro-Dex, Inc.:

Pro-Dex, Inc., with operations in California and Oregon, specializes in the design, development and manufacture of powered rotary drive surgical and dental instruments used primarily in the orthopedic, spine, maxocranial facial and dental markets.  Its OMS division designs and manufactures embedded motion control systems serving the medical, dental, semi-conductor and scientific research markets. Pro-Dex’s products are found in hospitals, dental offices, medical engineering labs, scientific research facilities and high tech manufacturing operations around the world. For more information, visit the Company’s website at www.pro-dex.com.

Statements herein concerning the Company’s plans, growth and strategies may include ‘forward-looking statements’ within the context of the federal securities laws. Statements regarding the Company’s future events, developments and future performance, as well as management’s expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company’s actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company’s filings with the Securities and Exchange Commission.

(tables follow)

Fisher Communications (FSCI) to Explore Strategic Alternatives

SEATTLE, WA — (Marketwire) — 01/10/13 — Fisher Communications, Inc. (NASDAQ: FSCI) announced today that its Board of Directors has decided to explore and evaluate potential strategic alternatives intended to enhance shareholder value, which could result in, among other things, a possible sale of the Company. The Company has retained Moelis & Company as its financial advisor and White & Case LLP and Perkins Coie LLP as its legal counsel.

The Company has not made a decision to pursue any specific strategic transaction or any other strategic alternative, and there is no set timetable for the strategic review process. There can be no assurance that the exploration of strategic alternatives will result in the consummation of any transaction. The Company does not intend to comment further regarding the evaluation of strategic alternatives until such time as the Board has determined the outcome of the process or otherwise has deemed that disclosure is appropriate.

Due to the Board’s decision to explore and evaluate strategic alternatives, the Company will delay the date of its 2013 annual meeting of shareholders (the “Annual Meeting”) to a date that is not earlier than June 9, 2013. As a result, in accordance with the Company’s Amended Bylaws, nominations by shareholders for the election of Company directors at the Annual Meeting, and notice of other proper business, will be due on the later of: (i) the 90th day prior to the Annual Meeting, or (ii) the tenth day following the day on which the notice of the date of the Annual Meeting was mailed to shareholders or such public disclosure was made.

About Fisher Communications, Inc.
Fisher Communications, Inc. is a Seattle-based communications company that owns and operates 13 full power television stations, 7 low power television stations, 3 owned radio stations and one managed radio station in the Western United States. The Company also owns and operates Fisher Interactive Network, its online division (including over 120 online sites), and Fisher Pathways, a satellite and fiber transmission provider. For more information about Fisher Communications, Inc., go to www.fsci.com.

Forward-Looking Statements
This news release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Forward-looking statements include information preceded or followed by, or that includes, the words “guidance,” “believes,” “expects,” “intends,” “anticipates,” “could,” or similar expressions. For these statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this news release, including, among other things, statements related to the outcome of the Board of Directors’ strategic review and evaluation of the Company, changes in revenue, cash flow and operating expenses, involve risks and uncertainties and are subject to change based on various important factors, including the impact of changes in national and regional economies, the competitiveness of political races and voter initiatives, successful integration of acquired television stations (including achievement of synergies and cost reductions), pricing fluctuations in local and national advertising, future regulatory actions and conditions in the television stations’ operating areas, competition from others in the broadcast television markets served by the Company, volatility in programming costs, the effects of governmental regulation of broadcasting, industry consolidation, technological developments and major world news events. Unless required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this news release might not occur. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this release. For more details on factors that could affect these expectations, please see the risk factors in our Annual Report on Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities Exchange Commission, which are incorporated herein. Our Annual Report on Form 10-K and other periodic reports are available at the website maintained by the SEC at www.sec.gov.

Contacts:

Sard Verbinnen & Co
Ron Low or David Isaacs

Unwired Planet (UPIP) Strengthens Mobile Intellectual Property Portfolio

Unwired Planet Strengthens Mobile Intellectual Property Portfolio with the Contribution of Complementary IP from the Industry Leader in Mobile Communications

Unwired Planet, Inc. (NASDAQ: UPIP) (“Unwired Planet” or the “Company”), the inventor of the mobile Internet, today announced that it has entered into a patent purchase agreement with Ericsson (NASDAQ:ERIC) whereby Ericsson will transfer to Unwired Planet 2,185 issued US and international patents and patent applications.

The transferred patents significantly broaden Unwired Planet’s Mobile Internet-focused portfolio and include 753 United States issued patents related to 2G, 3G and LTE technologies. Under the terms of the transaction, Ericsson will also contribute 100 additional patent assets annually to Unwired Planet commencing in 2014 through 2018. Unwired Planet will compensate Ericsson with certain ongoing rights in future revenues generated from the enlarged patent portfolio. Unwired Planet will also grant Ericsson a license to the Company’s enlarged patent portfolio.

The combined portfolio reflects decades of significant investment in research and development and the companies’ respective roles as pioneers in the development of technology critical to Telecommunications Infrastructure and the Mobile Internet. The contributed Ericsson portfolio includes patented inventions relating to global telecommunication technologies, such as GSM, GPRS, EDGE, WCDMA and LTE, as well as many other patented inventions that are widely implemented in many popular wireless devices and mobile industries.

Following the transaction, Unwired Planet will execute a strategy as a long-term industry platform for the realization of intellectual property value across the global telecoms and mobile handset markets.

“Ericsson and Unwired Planet teamed in the late 1990’s at the dawn of the mobile Internet to define an industry and develop technology at the cutting edge of mobile communications. Our mobile heritage reflects decades of pioneering new technology, supported by billions of dollars in research and development. Our inventions have delivered massive social value and this transaction with Ericsson reflects our commitment to protecting and realizing value from this innovation,” said Mike Mulica, Chief Executive Officer of Unwired Planet. “We look forward to leveraging a strong, multi-dimensional patent portfolio and furthering discussions with key industry players who are interested in licensing these inventions to protect and further build their product strategies.”

“In 1997, Ericsson and Unwired Planet introduced the Wireless Application Protocol that brought Internet access to mobile devices,” said Kasim Alfalahi, Chief Intellectual Property Officer, Ericsson. “Following this transaction, Unwired Planet’s portfolio will reflect decades of invention at the forefront of mobile infrastructure, handset technologies and over-the-top services. We are pleased to have concluded this business deal with Unwired Planet as an alternative channel for IP licensing.”

Further details of the transaction are included in a Form 8-K to be filed by Unwired Planet with the United States Securities and Exchange Commission.

Conference Call Information

Unwired Planet has scheduled a conference call for 5:00 p.m. EST today to discuss the patent purchase agreement. Interested parties may access the conference call over the Internet through Unwired Planet’s website at www.unwiredplanet.com or by telephone at (877) 941-2068 or (480)-629-9712 (international). A replay of the conference call will be available for three weeks (until January 31), beginning at 6:00 pm EST on January 10 by calling (800) 406-7325. The replay can be accessed internationally by calling (303) 590-3030, access code: 4590216.

About Unwired Planet

Unwired Planet, Inc. (NASDAQ: UPIP) is the inventor of the mobile Internet and established many of the foundational patented technologies that allow mobile devices to connect to the Internet. The company’s 202 issued US and foreign patents and 75 pending applications are considered foundational to mobile communications, and span smart devices, cloud technologies and unified messaging. Unwired Planet’s portfolio includes patents related to key mobile application technologies, including mobile browsers, mobile advertising, push technology, maps and location based services, mobile application stores, social networking, mobile gaming and mobile search. Unwired Planet is headquartered in Reno, Nevada.

Safe Harbor for Forward-Looking Statements

This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this release are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. These forward-looking statements are subject to a number of risks, including, but not limited to the ability of the parties to the patent purchase agreement to consummate the proposed transaction in light of the various closing conditions set forth in the transaction documents (including those conditions related to HSR approval), the expiration of encumbrances on the patent portfolio, the potential value and synergies created by the transaction, including the future market for smartphones and 3G/4G mobile phone shipments and the ability of the Company to realize and monetize the value of the Company’s intellectual property as well as those risk factors discussed in filings with the SEC, including but not limited to the Company’s Annual Report on Form 10-K filed on September 7, 2012, and any subsequently filed reports on Forms 10-Q and 8-K or amendments thereto. The Company undertakes no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this release.

Rosetta Genomics (ROSG) Reports Study Comparing microRNA Profiles of Cancer

Rosetta Genomics Reports Study Comparing microRNA Profiles of Cancer of Unknown Primary and Metastases of Known Primary Tumors Published in Clinical Experimental Metastasis

PHILADELPHIA and REHOVOT, Israel, Jan. 9, 2013 /PRNewswire/ — Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study assessing the differences between cancer of unknown primary (CUP) and metastatic solid tumors of known primary metastases (KPM) by profiling microRNA expression were recently published in Clinical Experimental Metastasis, in an article entitled “Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors.”  The article can be viewed online at http://www.ncbi.nlm.nih.gov/pubmed/23124598.

The study assessed microRNA differences between CUP metastases with favorable prognosis and metastases of known primary tumors in order to screen for an aggressive, pro-metastatic, CUP-specific biologic signature.

The study consisted of two stages. In the first stage, metastases obtained from CUP cases were assigned to a primary tissue of origin using Rosetta’s miRview^® mets² microarray assay and compared to pathological and clinical presentation. In the second stage, the expression of 733 microRNAs was examined in CUP tumors classified as breast, serous ovarian and upper squamous cancers and compared to that of matched KPMs.

The study evaluated approximately 100 CUP and KPM tumors and found no unique microRNA signature differentiating CUP presentation from that of metastases of known primaries.  This supports current gold standard treatment for patients with favorable prognosis CUP, who are managed similarly to those with equivalent metastatic tumors of known primary. This study was a sub-set of a larger retrospective study assessing the performance of the miRview mets² assay in a cohort of real CUP patients.  The results of that study demonstrated that miRview mets² assay showed agreement with pathological and clinical information in 92% of cases.  Those data have been presented at medical conferences and are expected to be published in a separate peer-reviewed journal article.

Study author, George Pentheroudakis, M.D., Department of Medical Oncology at the University of Ioannina Medical School in Ioannina, Greece, noted, “This research is the first look for microRNA characteristics of CUP tumors. Study results confirmed epidemiologic evidence suggesting that patients with favorable prognosis CUP have a presentation, response to therapy and outcome no different from metastatic tumors of matched primaries.”

“This publication demonstrates the utility of microRNA profiling in understanding the biology of CUP and may have important implications for the prognosis and treatment of CUP patients,” stated Kenneth A. Berlin, President and CEO of Rosetta Genomics.  “We look forward to the publication of the full data set which we believe continues to underscore the clinical value of our miRview mets² assay in identifying the primary tumor type in CUP patients in order to optimize treatment protocols and potentially improve clinical outcomes.”

About Cancer of Unknown Primary Origin

According to the American Cancer Society, an estimated 2 to 5 percent of all cancer patients have metastatic (secondary) tumors for which routine testing cannot locate the primary site. This is called cancer of unknown primary origin. Patients may be diagnosed with cancer of unknown primary origin if the primary tumor is too small to be identified with routine imaging tests, it regresses (disappears) before a secondary tumor arises or the secondary tumor has several possible primary sites. Cancer of unknown primary origin can appear anywhere in the body, but is most commonly found in the lymph nodes, liver, lungs, bones or skin.

The miRview mets² assay measures the expression level of 64 microRNA biomarkers, which are then processed by an algorithm composed of two classifiers and a decision-maker that can accurately identify the origin of the patients’ tumor for 42 different cancer tissue types, with 85 percent sensitivity and 99 percent specificity. Clinicians use Rosetta Genomics’ assay to better diagnose CUP patients and get them on more optimal treatment plans.

About miRview^® Products

miRview^® are a series of microRNA-based diagnostic products offered by Rosetta Genomics. miRview^® mets² accurately identifies the primary tumor type in primary and metastatic cancer including CUP. miRview^® meso diagnoses mesothelioma, a cancer connected to asbestos exposure.  miRview^® lung accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. miRview^® kidney accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.  miRview^® tests are designed to provide objective diagnostic data; it is the treating physician’s responsibility to diagnose and administer the appropriate treatment.  In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the miRview^® mets² test, 60,000 from miRview^® meso, 54,000 from miRview^® kidney and 226,000 patients from miRview^® lung. The Company’s assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit www.mirviewdx.com. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics.  Founded in 2000 Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta’s miRview® product line is commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.  Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, statements relating to Rosetta’s strategic plan, the market acceptance of Rosetta’s miRview^® assays, particularly miRview^® mets², Rosetta’s capitalization of its microRNA platform and Rosetta’s development of personalized medicine products constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the “Risk Factors” section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2011 as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Mattson (MTSN) Increases Etch Product Line Growth With Shipment to Major Foundry

FREMONT, CA — (Marketwire) — 01/09/13 — Mattson Technology, Inc. (NASDAQ: MTSN), a leading supplier of advanced semiconductor processing equipment, today announced that it has shipped an etch system to a major foundry, the sixth semiconductor manufacturer now using its etch systems. The etch system will support development and production of advanced devices at leading-edge technology nodes at this foundry’s R&D facility.

“As the industry moves to lower technology nodes, the increased cost of designing and manufacturing integrated circuits becomes even more of a challenge for our customers,” said Rene George, vice president and general manager of the Plasma Products Group. “To stay on the leading-edge of each new chip generation, foundries require the most cost-effective and technologically advanced equipment to achieve the required return on their investments for expanding fab capacities. Mattson Technology’s etch tool was selected as a result of our systems’ proven track record of achieving optimal process performance for the most advanced technology nodes while delivering industry-leading cost of ownership. We are extending our etch presence in the foundry market with this sixth etch placement, and we look forward to continue providing leading-edge tools to support its production ramp of next-generation chips.”

About Mattson Technology, Inc.
Mattson Technology, Inc. designs, manufactures and markets semiconductor wafer processing equipment used in the fabrication of integrated circuits. We are a leading supplier of plasma and rapid thermal processing equipment to the global semiconductor industry, and operate in three primary product sectors: Dry Strip, Rapid Thermal Processing and Etch. Through manufacturing and design innovation, we have produced technologically advanced systems that provide productive and cost-effective solutions for customers fabricating current- and next-generation semiconductor devices. For more information, please contact Mattson Technology, Inc., 47131 Bayside Parkway, Fremont, CA, 94538. Telephone: (800) MATTSON / (510) 657-5900. Internet: www.mattson.com.

“Safe Harbor” Statement Under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to statements of the plans, strategies and objectives of management for future operations. Forward-looking statements address matters that are subject to a number of risks and uncertainties that can cause actual results to differ materially from those expressed or implied by such forward-looking statements and assumptions. Such risks and uncertainties include, but are not limited to: macroeconomic and geopolitical trends and events; end-user demand for semiconductors; customer demand for semiconductor manufacturing equipment; the timing of significant customer orders for the Company’s products; customer acceptance of delivered products and the Company’s ability to collect amounts due upon shipment and upon acceptance; the Company’s ability to timely manufacture, deliver and support ordered products; the Company’s ability to bring new products to market and to gain market share with such products; customer rate of adoption of new technologies; risks inherent in the development of complex technology; the timing and competitiveness of new product releases by the Company’s competitors; the Company’s ability to align its cost structure with market conditions; and other risks and uncertainties described in the Company’s Forms 10-K, 10-Q and other filings with the Securities and Exchange Commission. The Company assumes no obligation to update the information provided in this news release.

Mattson Technology Contact
Lauren Vu
Mattson Technology, Inc.
tel +1-510-492-6250
fax +1-510-492-5914
lauren.vu@mattson.com

Investor Contact
J. Michael Dodson
Mattson Technology, Inc.
tel +1-510-657-5900
fax +1-510-492-5963

Interactive Intelligence (ININ) Announces Strong Finish to 2012

Interactive Intelligence Group Inc. (Nasdaq: ININ), a global provider of unified IP business communications software and services, today announced preliminary results for its fourth quarter and full year ended Dec. 31, 2012.

“We had a remarkable end to a record year for orders and revenues in 2012,” said Interactive Intelligence founder and CEO, Dr. Donald Brown. “The business showed excellent growth across the board, with our fourth-quarter performance driven by sales momentum for both our cloud and premises-based offerings as we continue to gain share at the high end of the contact center market. We received an unprecedented 20 orders of over $1 million in the fourth quarter involving some of the largest companies in the world.

“Given our strong and growing pipeline of opportunities worldwide, we are maintaining our 2013 total order growth forecast of 20 percent and currently estimate that approximately 50 percent of these orders will be cloud-based.”

Highlights of orders include the following:

• Total orders received during the fourth quarter of 2012 grew 119 percent year-over-year, with a 312 percent increase in cloud-based orders and a 68 percent increase in on-premises orders.
• Cloud-based orders represented 39 percent of total orders received during the fourth quarter of 2012.
• Total orders for the full year of 2012 increased 48 percent from 2011, including an increase in cloud-based orders of 121 percent and growth of on-premises orders of 25 percent.
• For 2012, cloud-based orders represented 35 percent of the total order mix and on-premises orders represented 65 percent.

The company currently expects to report total revenues for the 2012 fourth quarter between $70 million and $72 million, up approximately 21 to 24 percent year-over-year. For the full year of 2012, the company expects to report total revenues in the range of $237 million to $239 million, up approximately 13 to 14 percent year-over-year.

Non-GAAP operating margin is expected to be approximately 7 to 10 percent for the fourth quarter of 2012, and between 3 and 4 percent for the full year of 2012.

Preliminary fourth-quarter and full year 2012 non-GAAP operating margins exclude stock-based compensation expense of approximately $1.7 million and $6.7 million, respectively, and purchase-related adjustment to revenue and amortization of intangibles of approximately $770,000 and $2.5 million, respectively.

The company has not completed preparation of its audited financial statements for the year ended Dec. 31, 2012. These preliminary results may be subject to adjustments and could change materially.

For the full year of 2013, based on the forecasted 20 percent order growth with cloud-based orders representing approximately 50 percent of total orders, the company expects 2013 revenues to be in the range of $285 million to $290 million with a non-GAAP operating margin of 3 to 5 percent.

“We expect our non-GAAP operating margin to be in the low single digits in 2013 due to the rapid growth of our cloud-based orders and our further investments in cloud solutions and sales,” Brown said. “Interactive Intelligence is solidifying its position as a leader in the cloud-based contact center market, and we plan to extend that position by continuing to accelerate our pace of innovation in the coming year.”

Interactive Intelligence plans to issue its final fourth-quarter and full year 2012 results on Feb. 4, 2013 after the market closes and will host a conference call that day at 4:30 p.m. Eastern time (EST) to review the company’s financial results and provide guidance for the first quarter and full year of 2013. The conference call will feature Dr. Brown and the company’s CFO, Stephen R. Head. A live Q&A session will follow opening remarks.

To access the teleconference, dial 1.877.324.1969 at least five minutes prior to the start of the call. Ask for the teleconference by the following name: “Interactive Intelligence fourth-quarter earnings call.”

The teleconference will also be broadcast live on the company’s investor relations’ page at http://investors.inin.com. An archive of the teleconference will be posted following the call.

About Interactive Intelligence

Interactive Intelligence Group Inc. (Nasdaq: ININ) is a global provider of contact center automation, unified communications, and business process automation software and services. The company’s unified IP business communications solutions, which can be deployed on-premises or via the cloud, are ideal for industries such as financial services, insurance, outsourcers, collections, and utilities. Interactive Intelligence was founded in 1994 and has more than 5,000 customers worldwide. The company is among Forbes Magazine’s 2011 Best Small Companies in America and Software Magazine’s 2012 Top 500 Global Software and Service Providers. It employs approximately 1,400 people and is headquartered in Indianapolis, Indiana. The company has offices throughout North America, Latin America, Europe, Middle East, Africa and Asia Pacific. Interactive Intelligence can be reached at +1 317.872.3000 or info@inin.com; on the Net: www.inin.com.

*Non-GAAP Measures

The non-GAAP measures shown in this release include revenue which was not recognized on a GAAP basis due to purchase accounting adjustments and exclude non-cash stock-based compensation expense for stock options, the amortization of certain intangible assets related to acquisitions by the company and non-cash income tax expense. These measures are not in accordance with, or an alternative for, GAAP and may be different from non-GAAP measures used by other companies. Stock-based compensation expense and amortization of intangibles related to acquisitions are non-cash and certain amounts of income tax expense are non-cash. Management believes that the presentation of non-GAAP results, when shown in conjunction with corresponding GAAP measures, provides useful information to management and investors regarding financial and business trends related to the company’s results of operations. Further, management believes that these non-GAAP measures improve management’s and investors’ ability to compare the company’s financial performance with other companies in the technology industry. Because stock-based compensation expense, non-cash income tax expense amounts and amortization of intangibles related to acquisitions can vary significantly between companies, it is useful to compare results excluding these amounts. Management also uses financial statements that exclude stock-based compensation expense related to stock options, non-cash income tax amounts and amortization of intangibles related to acquisitions for its internal budgets.

Forward Looking Statements

This release may contain certain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially are the following: rapid technological changes in the industry; the company’s ability to maintain profitability; to manage successfully its growth; to manage successfully its increasingly complex third-party relationships resulting from the software and hardware components being licensed or sold with its solutions; to maintain successful relationships with certain suppliers which may be impacted by the competition in the technology industry; to maintain successful relationships with its current and any new partners; to maintain and improve its current products; to develop new products; to protect its proprietary rights adequately; to successfully integrate acquired businesses; and other factors described in the company’s SEC filings, including the company’s latest annual report on Form 10-K.

Interactive Intelligence is the owner of the marks INTERACTIVE INTELLIGENCE, its associated LOGO and numerous other marks. All other trademarks mentioned in this document are the property of their respective owners.

VOXX International (VOXX) Reports Fiscal 2013 Q3 Results

HAUPPAUGE, N.Y., Jan. 9, 2013 /PRNewswire/ — VOXX International Corporation (NASDAQ: VOXX), today announced financial results for its fiscal 2013 third quarter ended November 30, 2012.

Fiscal Third Quarter Highlights:

• Sales increased 17.5%, driven by the Hirschmann acquisition and increases in mobile OEM and in accessories.
• Gross margins of 28.8% ahead of internal projections due to product mix and increases in select categories; operating expenses, excluding Hirschmann decreased by $2.1 million or 5.1%.
• Company reports net income of $13.2 million or $0.56 per diluted share, up $4.3 million.
• EBITDA of $25.8 million, increased $6.6 million; Adjusted EBITDA of $25.7 million, increased $3.5 million.
• Fiscal 2013 nine-month Adjusted EBITDA of $49.1 million, up $7.0 million; Company reaffirms FY13 Adjusted EBITDA guidance of $61 million on strength of 3Q performance.

Commenting on the Company’s performance, Pat Lavelle, President and CEO stated, “From a bottom-line perspective, we had one of the best quarters in our history and our business performed well, especially considering continued weakness in the international markets.  Our domestic operations met plan with sales reaching targets and gross margins slightly ahead of internal projections.  We’ve also placed greater emphasis on managing our core overhead and saw expenses, less Hirschmann, decline by over 5%.  What we can control, we’re controlling and we’re on track to deliver the Adjusted EBITDA guidance we gave last quarter.”

Lavelle continued, “Domestically, we had strong placement at retail driven by new products and through new channels.  We also saw increases in our mobile OEM business on the heels of programs with Ford and Nissan which began last quarter.  While overall retail sales during the Holiday season were lighter than anticipated, we’re hoping the recently passed legislation will provide some clarity for consumers and give them confidence moving into 2013.  With modest improvements in Germany and China, coupled with continued strength in our core domestic markets, we should be well positioned to improve on our performance next year, especially with new products coming to market in the 2^nd half of the calendar year.  The reception we’ve received so far at the Consumer Electronics Show this week has been nothing short of spectacular.”

Fiscal Third Quarter Performance
Net sales for the fiscal 2013 third quarter were $243.0 million, an increase of 17.5% compared to net sales of $206.8 million in the comparable year ago period.

Electronics sales were $201.5 million and $165.9 million for the comparable fiscal third quarters, an increase of 21.4%.  Driving this increase was primarily the addition of Hirschmann sales, which accounted for $39.5 million during the fiscal 2013 third quarter.  Excluding the impact of Hirschmann, Electronics sales declined approximately $3.9 million or 2.4% with the declines primarily in consumer products, mobile audio and in the international markets.  Offsetting this decline were increases in mobile OEM sales, particularly at Invision on the strength of new OEM programs with Ford and Nissan for rear-seat entertainment, higher sales of headphones and sound bars, and new product offerings. For the three months ended November 30, 2012, Electronics sales represented 82.9% of net sales as compared to 80.2% in the comparable prior year period.

Accessories sales for the fiscal 2013 third quarter were $41.6 million, an increase of 1.7% as compared to sales of $40.9 million in the comparable prior year period.  The Accessories group was favorably impacted by higher domestic sales of new wireless speakers, digital antennas and both portable power lines and power supply systems.  This growth was partially offset by declines internationally.  Accessories represented 17.1% of net sales for the three months ended November 30, 2012 as compared to 19.8% in the comparable prior year period.

The gross margin for the three months ended November 30, 2012 was 28.8%, a decrease of 10 basis points as compared to 28.9% for the fiscal 2012 third quarter, though margins did come in ahead of internal projections.  This slight year-over-year decline was principally due to unfavorable swings between hedged costs and related sales, as well as lower sales of higher margin car speakers at Audiovox Germany.  This was offset by higher margins in select consumer, accessories and mobile product categories, the addition of Hirschmann sales, and as a result of exiting some lower margin products.  The Company reiterated its prior gross margin guidance of 28.0% for the fiscal year.

Operating expenses for the fiscal 2013 third quarter were $50.2 million, an increase of $8.8 million over $41.4 million reported in the fiscal 2012 third quarter. As a percentage of net sales, operating expenses increased to 20.6% as compared to 20.0% for the periods ended November 30, 2012 and November 30, 2011, respectively.  The increase in operating expenses was primarily driven by the addition of Hirschmann, which accounted for $10.9 million, as well as increases advertising expenses.  Offsetting this were reductions in depreciation expense, sales commissions and professional fees, not considering Hirschmann, headcount reductions in select groups, and lower occupancy costs due to the purchase of the Klipsch headquarters.  Excluding the addition of Hirschmann expenses, operating expenses declined $2.1 million for the comparable quarters or 5.1%.

The Company reported operating income of $19.8 million for the fiscal 2013 third quarter compared to operating income of $18.4 million in the comparable year ago period, an increase of $1.4 million or 7.3%.  Net income for the quarter ended November 30, 2012 was $13.2 million or net income per diluted share of $0.56 as compared to net income of $8.9 million and net income per diluted share of $0.38 for the period ended November 30, 2011.

Earnings before interest, taxes, depreciation and amortization (EBITDA) for the fiscal 2013 third quarter, was $25.8 million as compared to EBITDA of $19.2 million for the comparable period in fiscal 2012, an improvement of $6.6 million.  Taking into account stock-based compensation, Klipsch settlement recoveries and Asia restructuring charges, the Company reported Adjusted EBITDA of $25.7 million as compared to $22.2 million in the comparable year-ago period.  Fiscal 2012 third quarter also includes a $2.6 million net settlement charge related to the patent infringement suit.  The Company reported Diluted Adjusted EBITDA per common share of $1.09 as compared to $0.96 for the same periods as noted above.

Nine Month Comparisons
Net sales for the fiscal 2013 nine month period ended November 30, 2012 were $628.8 million, an increase of 18.5% compared to net sales of $530.5 million in the comparable year ago period.  Electronics sales were $510.6 million and $425.0 million for the comparable nine month periods, an increase of 20.1%.  Driving this increase was primarily the addition of Hirschmann sales, which accounted for $115.7 million, higher sales to mobile OEMs and increases in sales of headphones and sound bars, as well as new product offerings.  Offsetting this growth were declines in consumer products, as part of the Company’s strategy to exit certain lower margin categories, lower sales of mobile audio and security products in the aftermarket and declines of car speaker sales in Europe.  Through the first nine months of fiscal 2013, Electronics sales represented 81.2% vs. 80.1% for the comparable nine-month period last year.

Accessory sales increased by $12.7 million or by 12.0%, driven primarily by the continued increase in domestic sales of new wireless speakers, digital antennas and both portable power lines and power supply systems, partially offset by declines internationally. As a percentage of net sales, Accessories represented 18.8% vs. 19.9% for the comparable nine-month periods ended November 30, 2012 and November 30, 2011, respectively.

The gross margin for the nine months ended November 30, 2012 was 27.9%, an increase of 10 basis points as compared to 27.8% for the same period last year.  The increase in gross margins was principally due to higher sales of OEM related products, higher margins of select consumer accessories products including wireless Bluetooth speakers, headphones and sound bars, as well as the Hirschmann acquisition.  These increases were partially offset by the unfavorable swings between hedged costs and related sales, increased freight costs and slower car speaker sales at Audiovox Germany, and the shift in the Company’s warehouse facilities in Asia.

Operating expenses for the fiscal 2013 nine month period were $145.4 million, an increase of $28.1 million over $117.3 million reported in the comparable fiscal 2012 period.  This increase was primarily driven by the addition of Hirschmann expenses, which accounted for $32.1 million, as well as higher advertising expenses.  Excluding the addition of Hirschmann expenses, operating expenses declined $4.0 million for the comparable nine month periods, or 3.4%.

The Company reported operating income of $29.7 million for the fiscal 2013 nine month period compared to operating income of $30.1 million in the comparable year ago period.  Net income for the nine-month period ended November 30, 2012 was $12.2 million or net income per diluted share of $0.52 as compared to net income of $14.8 million and net income per diluted share of $0.64 for the nine-month period ended November 30, 2011.  Net income decreased versus the comparable year primarily as a result of expenses associated with the patent lawsuit and losses on forward exchange contracts, partially offset by decreased tax provisions and the addition of the Hirschmann acquisition.

Earnings before interest, taxes, depreciation and amortization (EBITDA) for the fiscal 2013 nine month period, was $36.4 million as compared to EBITDA of $37.2 million for the comparable period in fiscal 2012.  Taking into account stock-based compensation, net settlement charges related to the patent litigation, Asia restructuring charges, settlement recoveries at Klipsch, acquisition related costs, and losses on foreign exchange contracts as a result of the Hirschmann acquisition, the Company reported Adjusted EBITDA of $49.1 million as compared to $42.1 million in the comparable year-ago period, an improvement of $7.0 million.  Diluted adjusted EBITDA per common share for the fiscal 2013 nine month period was $2.08 as compared to $1.82 for the same period in fiscal 2012.

Non-GAAP Measures
Adjusted EBITDA and diluted adjusted EBITDA per common share are not financial measures recognized by GAAP. Adjusted EBITDA represents net income, computed in accordance with GAAP, before interest expense, taxes, depreciation and amortization, stock-based compensation expense, litigation settlements, restructuring charges and costs and foreign exchange gains or losses relating to our acquisitions. Depreciation, amortization, and stock-based compensation expense are non-cash items. Diluted adjusted EBITDA per common share represents the Company’s diluted earnings per common share based on adjusted EBITDA.

We present adjusted EBITDA and diluted adjusted EBITDA per common share in this Form 10-Q because we consider them to be useful and appropriate supplemental measures of our performance. Adjusted EBITDA and diluted adjusted EBITDA per common share help us to evaluate our performance without the effects of certain GAAP calculations that may not have a direct cash impact on our current operating performance. In addition, the exclusion of costs and foreign exchange gains or losses relating to our acquisitions, litigation settlements and restructuring charges allows for a more meaningful comparison of our results from period-to-period. These non-GAAP measures, as we define them, are not necessarily comparable to similarly entitled measures of other companies and may not be appropriate measures for performance relative to other companies.  Adjusted EBITDA should not be assessed in isolation from or construed as a substitute for EBITDA prepared in accordance with GAAP. Adjusted EBITDA and diluted adjusted EBITDA per common share are not intended to represent, and should not be considered to be more meaningful measures than, or an alternative to, measures of operating performance as determined in accordance with GAAP.

Conference Call Information
The Company will be hosting its conference call on Thursday, January 10, 2013 at 10:00 a.m. EST.  Interested parties can participate by visiting www.voxxintl.com, and clicking on the webcast in the Investor Relations section or via teleconference (toll-free number: 866-314-5050; international: 617-213-8051; pass code: 69980504).  For those who will be unable to participate, a replay will be available approximately one hour after the call has been completed and will last for one week thereafter (replay number: 888-286-8010; international replay: 617-801-6888; pass code: 50534816).

About VOXX International Corporation
VOXX International Corporation (NASDAQ:VOXX) is the new name for Audiovox Corporation, a company that was formed over 45 years ago as Audiovox that has grown into a worldwide leader in many automotive and consumer electronics and accessories categories, as well as premium high-end audio.  Through its wholly owned subsidiaries, VOXX International proudly is recognized as the #1 premium loudspeaker company in the world, and has #1 market positions in automotive video entertainment and remote starts, digital TV tuners and digital antennas.  The Company’s brands also hold #1 market share for TV remote controls and reception products and leading market positions across a wide-spectrum of other consumer and automotive segments.

Today, VOXX International is a global company….with an extensive distribution network that includes power retailers, mass merchandisers, 12-volt specialists and most of the world’s leading automotive manufacturers.   The company has an international footprint in Europe, Asia, Mexico and South America, and a growing portfolio, which is now comprised of over 30 trusted brands. Among the key domestic brands include Klipsch®, RCA®, Invision®, Jensen®, Audiovox®, Terk®, Acoustic Research®, Advent®, Code Alarm®, CarLink®, Excalibur® and Prestige®.  International brands include Hirschmann Car Communication®, Klipsch®, Jamo®, Energy®, Mirage®, Mac Audio®, Magnat®, Heco®, Schwaiger®, Oehlbach® and Incaar™.  The Company continues to drive innovation throughout all of its subsidiaries, and maintains its commitment to exceeding the needs of the consumers it serves.  For additional information, please visit our Web site at www.voxxintl.com.

Safe Harbor Statement
Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. The factors include, but are not limited to risks that may result from changes in the Company’s business operations; our ability to keep pace with technological advances; significant competition in the mobile and consumer electronics businesses as well as the accessories  business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against VOXX International Corporation and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company’s Form 10-K for the fiscal year ended February 29, 2012.

Company Contact :
Glenn Wiener, GW Communications
Tel: 212-786-6011 / Email: gwiener@GWCco.com

NewLead Holdings (NEWL) Receives Investment of $236.4 million

PIRAEUS, Greece, Jan. 9, 2013 /PRNewswire/ — NewLead Holdings Ltd. (NASDAQ: NEWL) (“NewLead”) today announced that the Company received a capital contribution of industrial metal valued at $236.4 million for a 36.8% equity interest in NewLead.

Michael Zolotas, President and Chief Executive Officer of NewLead, stated, “this significant investment demonstrates confidence in the management team and the future of NewLead.  The investment will provide valuable collateral for loans funding our capital-intensive activities and provides a solid platform to execute on our diversified growth strategy.”

Upon completion of this transaction, it is expected that NewLead will have a total of 701,904,963 shares of common stock outstanding. NewLead will issue, following NASDAQ’s approval, unregistered shares in exchange for the new investment. The new shareholder has agreed, subject to certain limited exceptions, not to pledge, borrow or dispose of the NewLead shares or otherwise transfer ownership of the shares until June 30, 2014. The new shareholder will not have board representation or other rights.

The value of the industrial metal was established on January 7, 2013 by an independent appraiser. The foreign currency exchange rate on January 7, 2013 was used for currency translation.

About NewLead Holdings Ltd.

NewLead Holdings Ltd. is an international, vertically integrated shipping and commodity company that manages product tankers and dry bulk vessels. NewLead currently controls four vessels, two tankers and two dry bulk vessels. NewLead’s common shares are traded under the symbol “NEWL” on the NASDAQ Global Select Market. To learn more about NewLead Holdings Ltd., please visit the new website at www.newleadholdings.com.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

This press release includes assumptions, expectations, projections, intentions and beliefs about future events. These statements, as well as words such as “anticipate,” “estimate,” “project,” “plan,” and “expect,” are intended to be ”forward-looking” statements. We caution that assumptions, expectations, projections, intentions and beliefs about future events may vary from actual results and the differences can be material. Forward-looking statements include, but are not limited to, such matters as future operating or financial results; our liquidity position and cash flows, our ability to borrow additional amounts under our revolving credit facility and, if needed, to obtain waivers from our lenders and restructure our debt, and our ability to continue as a going concern; statements about planned, pending or recent vessel disposals and/or acquisitions, business strategy, future dividend payments and expected capital spending or operating expenses, including dry-docking and insurance costs; statements about trends in the product tanker and dry bulk vessel shipping segments, including charter rates and factors affecting supply and demand; expectations regarding the availability of vessel acquisitions; completion of repairs; length of off-hire; availability of charters; and anticipated developments with respect to any pending litigation. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although NewLead believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, NewLead cannot assure you that it will achieve or accomplish these expectations, beliefs or projections described in the forward looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the strength of world economies and currencies, general market conditions, including changes in charter rates and vessel values, failure of a seller to deliver one or more vessels, and other factors discussed in NewLead’s filings with the U.S. Securities and Exchange Commission from time to time. NewLead expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in NewLead’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Investor and Media Relations:
Elisa Gerouki
NewLead Holdings Ltd.
Telephone: + 30 213 014 8023
Email: egerouki@newleadholdings.com

Majesco (COOL) and Disney Interactive Collaborate on Upcoming Video Game

EDISON, NJ — (Marketwire) — 01/08/13 — Majesco Entertainment Company (NASDAQ: COOL), an innovative provider of games for the mass market, announced today a relationship with Disney Interactive to start development of original video games based on the animated hit Disney television series Phineas and Ferb.

“We are thrilled to be teaming up with Disney to bring a new Phineas and Ferb game to market across multiple platforms,” said Jesse Sutton, Chief Executive Officer, Majesco Entertainment. “Phineas and Ferb is known for fun-filled adventures and hilarious gags that appeal to a universal audience, and we’re creating a game that leverages the characters and brand attributes of the highly successful series.”

The new game will be developed for retail consoles and gaming handhelds, including smartphones and tablets, and is scheduled for release in August 2013.

For more information on Majesco Entertainment, please visit www.majescoent.com, ‘Like’ us on Facebook or follow the company on Twitter @Majesco.

About Disney Interactive Media Group
Disney Interactive, one of the world’s largest creators of high-quality interactive entertainment across all platforms, is the part of The Walt Disney Company responsible for the global creation and delivery of interactive entertainment, multi-platform video games, and family-focused content across all current and emerging digital media platforms. Disney Interactive produces and distributes a broad portfolio of content from Disney Interactive Games and Disney Interactive Media. Products and content released and operated by Disney Interactive include blockbuster mobile, social and console games, online virtual worlds, #1 kid’s entertainment destination Disney.com and the #1 Family/Parenting portfolio on the Web.

Disney Interactive is the interactive entertainment part of The Walt Disney Company (NYSE: DIS).

About Majesco Entertainment Company
Majesco Entertainment Company is a leading developer and publisher of video games for the mass market. Building on more than 20 years of operating history, the company is focused on developing and publishing a wide range of casual and family oriented video games on all leading console and handheld platforms as well as online, social networks and mobile devices. Product highlights include Zumba® Fitness, Cooking Mama™ and NBA Baller Beats™. The company’s shares are traded on the Nasdaq Stock Market under the symbol: COOL. Majesco is headquartered in Edison, NJ with offices in San Francisco, CA, Brockhampton, UK, and a social games development studio in Foxboro, MA. More info can be found online at majescoent.com or on Twitter @Majesco.

Safe Harbor

Certain statements contained herein are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by reference to a future period(s) or by the use of forward-looking terminology, such as “may,” “will,” “intend,” “should,” “expect,” “anticipate,” “estimate” or “continue” or the negatives thereof or other comparable terminology. The Company’s actual results could differ materially from those anticipated in such forward-looking statements due to a variety of factors. These factors include but are not limited to, the demand for our products; our ability to complete and release our products in a timely fashion; competitive factors in the businesses in which we compete; continued consumer acceptance of our products and the gaming platforms on which our products operate; fulfillment of orders preliminarily made by customers; adverse changes in the securities markets and the availability of and costs associated with sources of liquidity. The Company does not undertake, and specifically disclaims any obligation, to release publicly the results of any revisions that may be made to any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Majesco Media Contact:
Tracie Snitker
Reverb Communications
209-586-1495 x104

Planet Payment (PLPM) to Present at the 15th Annual Needham Growth Conference

LONG BEACH, N.Y., Jan. 8, 2013 (GLOBE NEWSWIRE) — Planet Payment, Inc. (Nasdaq:PLPM) (LSE:PPT) (LSE:PPTR), a leading provider of international payment processing and multi-currency processing services, today announced that the Company will present at the 15th Annual Needham Growth Conference at the New York Palace Hotel in New York, N.Y. on Tuesday, January 15, 2013. The presentation will begin at 10:40 AM ET.

Investors and interested parties can access a live presentation by visiting the Company’s investor relations website at http://ir.planetpayment.com at the appropriate time.

About Planet Payment

Planet Payment is a leading provider of international payment processing and multi-currency processing services. We provide our services in 18 countries and territories across the Asia Pacific region, North America, the Middle East, Africa and Europe, primarily through our more than 45 acquiring bank and processor customers. Our point-of-sale and e-commerce services help merchants sell more goods and services to consumers, and together with our ATM services are integrated within the payment card transaction flow enabling our acquiring customers, their merchants and consumers to shop, pay, transact and reconcile payment transactions in multiple currencies, geographies and channels.

Planet Payment is headquartered in New York and has offices in Atlanta, Beijing, Bermuda, Delaware, Dubai, Dublin, London, Hong Kong, Mexico City, Shanghai and Singapore. Visit ww.planetpayment.com for more information about the Company and its services. For up-to-date information follow Planet Payment on Twitter at @PlanetPayment or join Planet Payment’s Facebook page.

CONTACT: Media Relations:

         Planet Payment
         Contact: Robert Cox, CFO
         Telephone: +1.516.670.3200 

         Redleaf Polhill (UK PR for Planet Payment)
         Contacts: Emma Kane / Henry Columbine / David Ison
         Telephone: +44.20.7566.6720
         Email:  planet@redleafpolhill.com

         ICR (US PR for Planet Payment)
         Contacts: Don Duffy / Dara Dierks
         Telephone: +1.646.277.1212

Methes (MEIL) Signs Letter of Intent to Deploy Its Technology in California

LAS VEGAS, NV — (Marketwire) — 01/08/13 — Methes Energies International Ltd. (NASDAQ: MEIL), a renewable energy company that offers an array of products and services to biodiesel fuel producers, announces that its wholly-owned subsidiary, Methes Energies Canada Inc., has signed a Letter of Intent (LOI) with U.S. Energy Initiatives Corp. of Santa Clarita, California (a public company traded under the symbol (PINKSHEETS: USEI)) to initially acquire, among other things, one of our Denami 600 biodiesel processors.

U.S. Energy Initiatives plans to set up its first 1.3 million gallons per year (mgy) production facility in California and use the site as a showcase to market and promote our Denami 600 and Denami 3000 biodiesel processors. Our Denami 600 processors and Denami 3000 processors, respectively, have a maximum rated biodiesel production capacity of 1.3 mgy and 6.5 mgy. The intent is to eventually set up additional facilities in California and across the U.S. as close as possible to feedstock supplies in order to minimize transportation and logistics.

“Our goal is to build a strong biodiesel division using a technology that is already proven and reliable,” said U.S. Energy Initiatives CEO, Anthony Miller. “The Methes business model is truly unique and does not only focus on technology, but also on all of the aspects of biodiesel production and distribution, including product quality, compliance, production, marketing and logistics. Methes’ experience and track record are two strong assets to us that we intend to make the most of.”

Nicholas Ng, President of Methes Energies, said, “We look forward to working with Anthony and his team. They have a comprehensive understanding of biodiesel and a plan to take advantage of the growing demand. With the $1.00 per gallon tax credit back in the U.S., we expect a strong 2013 and beyond.”

About U.S. Energy Initiatives Corp.
U.S. Energy Initiatives Corp, is a diverse energy firm that has a long history of developing automotive and hybrid fuel systems and technologies. This firm started in 1996 and has since become a successful developer of its business strategies. Its Management’s new goal is to also develop new and old technologies, as well as to build a dynamic energy firm. The Company has three separate energy initiatives; one in the oil, gas & technology sector (brought in by Mr. Miller), one in the hybrid fuel or biofuel sector and one in the automotive sector. The firm’s immediate goal is to create its own biofuel opportunities and going forward, to acquire and develop stranded or un-recovered oil properties for enhanced oil production, forming partnerships with operators, in addition to the elaboration of strategic alliances for primary and secondary recovery. The company’s overall goal is to become environmentally responsible in the energy sector, utilizing all of the methods available to create a continued financial growth. Toward achieving that purpose, it will market its products throughout the world to significantly increase revenues, while adding value for its shareholders.

About Methes Energies International Ltd.
Methes Energies International Ltd. is a renewable energy company that offers a variety of products and services to biodiesel fuel producers. Methes also offers biodiesel processors that are unique, truly compact, fully automated state-of-the-art and continuous flow that can run on a wide variety of feedstocks. Methes markets and sells biodiesel fuel produced at its showcase production facility in Mississauga, Ontario, Canada and at its recently commissioned 13 MGY facility in Sombra, Ontario, to customers in the U.S. and Canada, as well as providing multiple biodiesel fuel solutions to its clientele. Among its services are selling commodities to its network of biodiesel producers, selling their biodiesel production and providing clients with proprietary software to operate and control their processors. Methes also remotely monitors the quality and characteristics of its clients’ production, upgrades and repairs their processors and advises clients on adjusting their processes to use varying feedstock to improve the quality of their biodiesel. For more information, please visit www.methes.com.

This press release contains forward-looking statements regarding future events and financial performance. In some cases, you can identify these statements by words such as “may,” “might,” “will,” “should,” “except,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” the negative of these terms and other comparable terminology. These statements involve a number of risks and uncertainties and are based on numerous assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. There are or may be important factors that could cause our actual results to materially differ from our historical results or from any future results expressed or implied by such forward looking statements. These factors include, but are not limited to, those discussed under the section entitled “Risk Factors” in our Registration Statement on Form S-1, filed June 22, 2012, as amended, which is available at the U.S. Securities and Exchange Commission website at www.sec.gov. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. The Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts:
Methes Energies International Ltd.
Michel G. Laporte
Chairman and CEO
702-932-9964

100K Pathogen Genome Project Selects PacBio (PACB) SMRT® DNA Sequencing

PacBio Long Sequence Reads Provide Ability to Close Genomes; SMRT Kinetic Information Enables Epigenetic Characterization

MENLO PARK, Calif., Jan. 8, 2013 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB) provider of the PacBio^®RS High Resolution Genetic Analyzer, and the University of California, Davis (UC Davis) today announced a partnership for the 100K Pathogen Genome Project. As part of the project, Pacific Biosciences’ Single Molecule, Real-Time (SMRT^®) technology will be used to sequence the genomes from at least 1,000 foodborne pathogen samples to completion, and to elucidate their epigenomes. These bacteria represent major illness-causing pathogens, including Salmonella, Campylobacter, E. coli, Vibrio, and Listeria.

The 100K Genome Project was founded by the U.S. Food & Drug Administration, Agilent Technologies, and the laboratory of Dr. Bart Weimer at UC Davis to create a consortium of partners from around the world that will sequence 100,000 foodborne pathogens using next-generation sequencing. This initiative addresses a significant shortage of bacterial pathogen information for use in designing molecular diagnostics, creates a resource to expand our understanding of infection mechanisms, and constructs a public repository for new insights into bacterial evolution by using large-scale genomics.

Pacific Biosciences’ SMRT sequencing technology generates sequence reads an order of magnitude longer than other leading DNA sequencing technologies, thereby facilitating efficient de novo microbial genome assemblies. Long reads are critical for resolving genetic complexity in the assembly and finishing of genomes. The use of SMRT sequencing for the automated finishing of microbial genomes has been demonstrated in multiple recent publications, including for the genetic analysis of the Haitian cholera and German E. coli outbreaks.

The kinetic information acquired during SMRT sequencing can be used to elucidate the epigenome of bacteria. Epigenetic DNA base modifications, such as methylation, play an important role in the phenotypic variation, adaptability and pathogenicity of many bacteria, but they have been difficult to study due to the lack of a sequencing method to detect them. As part of the 100K Genome Project, the epigenomes of the pathogenic strains subjected to SMRT sequencing will be characterized, adding an important dataset to public database repositories.

“SMRT sequencing has been shown to be a powerful technology for the comprehensive determination of microbial genomes and epigenomes,” said Dr. Jonas Korlach, Chief Scientific Officer of Pacific Biosciences. “Through the combination of long reads, high consensus accuracy, and the lack of sequencing bias to GC content or sequence contexts, SMRT sequencing harbors the necessary requirements to construct finished genomes in an unbiased, hypothesis-free manner. The ability to detect methylation as part of the sequencing process is unique to SMRT sequencing, and will provide an invaluable resource to illuminate the epigenetic components controlling bacterial pathogenicity.”

“We are very pleased to utilize SMRT sequencing as part of the 100K Genome Project,” said Bart Weimer, Professor and Director of the 100K Genome Project, “SMRT technology will enable production of complete genomes that will contribute great value toward databases for biological insight, new biomarker discovery, and reference genomes for food pathogen detection. A project of this scale is needed since microbial genome variations, including structural variations, the acquisition and loss of mobile elements, and phages or plasmids, are very difficult or impossible to detect without a de novo sequencing and genome assembly approach, yet they have a significant impact on food safety.”

The partnership will entail the sequencing of at least 1,000 samples by the 100K consortium member labs with access to the PacBio RS instrumentation, including pipeline constructions for high-throughput pathogen sequencing, de novo genome assemblies, epigenome determination, and data curation and deposition. Pacific Biosciences will provide technical guidance and training to support these activities, and interface closely with the involved laboratories to assist in the efficient construction of these pipelines.

For more information, please visit http://100kgenome.vetmed.ucdavis.edu/index.cfm and www.pacb.com.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers the PacBio^®RS High Resolution Genetic Analyzer to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT^®) technology, the company’s products enable: targeted sequencing to more comprehensively characterize genetic variations; de novo genome assembly to more fully identify, annotate and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems.

About The 100K Genome Project

Established in March 2012 by UC Davis, Agilent Technologies and the U.S. Food and Drug Administration, the 100K Genome Project is a landmark consortium that addresses the persistent food safety concerns by engaging world-wide partners to create a publicly available genetic database of the most common foodborne disease-causing microbes. By sequencing 100,000 pathogen genomes, the project will bring a new paradigm to public health to empower precise and robust molecular testing in the food chain – from the farm to the kitchen table. For more information, visit http://100kgenome.vetmed.ucdavis.edu.

About UC Davis

For more than 100 years, UC Davis has engaged in teaching, research and public service that matter to California and transform the world. Located close to the state capital, UC Davis has more than 33,000 students, more than 2,500 faculty and more than 21,000 staff, an annual research budget of nearly $750 million, a comprehensive health system and 13 specialized research centers. The university offers interdisciplinary graduate study and more than 100 undergraduate majors in four colleges — Agricultural and Environmental Sciences, Biological Sciences, Engineering, and Letters and Science. It also houses six professional schools — Education, Law, Management, Medicine, Veterinary Medicine and the Betty Irene Moore School of Nursing.

CONTACT: For Pacific Biosciences:

         Media:
         Maurissa Messier
         For Pacific Biosciences
         760.539.7417
         maurissa@bioscribe.com

         Investors:
         Trevin Rard
         Pacific Biosciences
         650.521.8450
         ir@pacificbiosciences.com

         For UC Davis:
         Media:
         Patricia Bailey
         Science/Agriculture writer
         UC Davis News Service
         (530) 752-9843 office
         (530) 219-9640 cell
         pjbailey@ucdavis.edu

         Scientific:
         Dr. Bart Weimer
         Professor, School of Veterinary Medicine
         Director, 100K Genome Project
         Director, BGI@UCDavis
         (530) 754-0109
         bcweimer@ucdavis.edu

Acasti Pharma (ACST) Shares to Trade on NASDAQ

LAVAL, Quebec, Jan. 7, 2013 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti“) (Nasdaq:ACST) (TSX-V:APO), a Neptune Technologies & Bioressources Inc. (“Neptune“) subsidiary, is pleased to announce that it has been approved to list its common shares on the NASDAQ Capital Market beginning on January 7, 2013 under the ticker symbol “ACST.”

“The listing of our common shares on the NASDAQ is an important milestone for Acasti,” stated Xavier Harland, Chief Financial Officer. “We believe our new listing will provide Acasti greater exposure to investors in the U.S. and around the world and reflects our effort to increase liquidity for our shareholders,” he added.

“We’re completing an important part of Acasti’s development plan with this listing. As set forth in Acasti’s business plan, the NASDAQ listing should be followed by the expected completion of the open label clinical trial,” said Harlan Waksal, Executive Vice-President. “There are multiple US institutional funds that are restricted from investing in shares that trade on foreign exchanges. We therefore believe that Acasti’s NASDAQ listing will broaden its base of potential shareholders,” he added.

About Acasti Pharma Inc.

Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma’s proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

“Neither NASDAQ nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports filed with the Securities and Exchange Commission and the Canadian securities commissions.

CONTACT: Acasti Contact:
         Xavier Harland
         Chief Financial Officer
         +1.450.687.2262
         x.harland@acastipharma.com
         www.acastipharma.com

         Howard Group Contact:
         Dave Burwell
         (888) 221-0915
         dave@howardgroupinc.com
         www.howardgroupinc.com

EntreMed (ENMD) Files New Drug Clinical Trial Application For ENMD-2076 With China SFDA

ROCKVILLE, Md., Jan. 7, 2013 /PRNewswire/ — EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that EntreMed has submitted a new drug clinical trial application with China’s State Food and Drug Administration (SFDA) for its proprietary drug candidate, ENMD-2076, to conduct global clinical trials in triple-negative breast cancer patients.

(Logo:  http://photos.prnewswire.com/prnh/20010620/ENMDLOGO )

Ken K. Ren, Ph.D., EntreMed’s Chief Executive Officer, commented, “We are very pleased with SFDA’s acceptance of our application package and look forward to working with the SFDA to move the process forward towards approval.  SFDA’s approval of our application would pave the way for us to conduct global clinical trials in China and advance our ongoing Phase 2 triple-negative breast cancer trial currently underway at the University of Colorado and Indiana University.

“Our filing with SFDA represents an important milestone for us.  As a clinical-stage drug development company, competition in patient recruitment, time, and costs can be challenging when advancing clinical programs. We address this by building a value-added platform via a joint US-China drug development model that will enable us to do the trials with lower study costs and faster patient recruitment.  The data we obtain may be used to support both global drug development and China import drug registration as appropriate.”

Dr. Ren continued, “We will also pursue developing ENMD-2076 in other indications where activity has been shown, including ovarian cancer, sarcoma and liver cancer, based on our prioritized product development plan.  We believe positive results from these efforts will add value to our patients, shareholders, as well as to the company.

“In addition, we have initiated local manufacturing and pre-clinical activities of ENMD-2076 in China to target specific unmet medical needs, such as hepatocellular carcinoma, which could support a new drug trial application with SFDA.  Our local development activities demonstrate EntreMed’s commitment to develop a strong presence in the Chinese market, which has been projected to become the second largest pharmaceutical market in coming years.  We believe we are on track with our development plan and are grateful to our shareholders for their enthusiasm, patience, and long term support.”

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective Aurora A and angiogenic kinase inhibitor for cancer, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer. EntreMed, Inc. recently initiated a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer.  Its second compound, 2ME2, has been investigated in clinical trials in oncology patients, and was the subject of a successful IND filing for clinical use to treat RA in 2006.  Additional information about EntreMed is available on the Company’s web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase.  Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.  ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers.  ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma.  ENMD-2076 is currently completing a Phase 2 trial for ovarian cancer.  EntreMed, Inc. recently initiated a Phase 2 study of ENMD-2076 in triple-negative breast cancer.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; declines in actual sales of Thalomid^® resulting in reduced royalty payments; risks associated with our product candidates; any early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission (“SEC”), which are available at www.sec.gov.

COMPANY CONTACT:
Investor Relations
EntreMed, Inc.
240.864.2643
investorrelations@entremed.com

Zoom (ZOOM) Announces Sale of China-Based Operations Strategy to Acquire U.S.-Based

BEIJING, Jan. 7, 2013 (GLOBE NEWSWIRE) — Zoom Technologies, Inc. (Nasdaq:ZOOM) a leading designer and manufacturer of mobile phones and consumer electronics, announced the execution of a definitive agreement pursuant to which it will sell its China-based manufacturing, sales and marketing, and R&D subsidiaries, and that the proceeds of the sale will be used for the purchase of additional U.S.-based businesses.

On December 31, 2012, Zoom Technologies, Inc. (“Zoom” or the “Company”) entered into a Share Purchase Agreement with the Beijing Zhumu Culture Communication Company, Ltd. (the “Purchaser”), a PRC company that provides services to the telecommunication industry, for the sale to the Purchaser of the Company’s China based operations including: 100% ownership of Beijing Nollec Wireless Company (“Nollec”) – the R&D subsidiary, 80% ownership of Tianjin Tongguang Group Digital Communication Company, Ltd. (“TCBD”) – the main manufacturing entity, 100% ownership of Profit Harvest Corporation, Ltd. (“Profit Harvest”) – the sales & marketing company, and 100% ownership of Celestial Digital Entertainment, Ltd. (“CDE”) – the mobile game maker. As consideration for the sale, the Purchaser shall pay the Company an aggregate of Rmb 200 million, equivalent to approximately US$32 million. The purchase price is, subject to adjustment pending an appraisal by an independent third party appraiser. As of the date of the Share Purchase Agreement, the Purchaser has deposited the full amount of RMB 200 million into an escrow account, to be released to the Company upon the final closing of the Sale, which will be held 30 days after the Company receives all the requisites corporate and regulatory approvals with respect to the Sale.

The Company’s ownership interest in SpreadZoom Technologies Co., Ltd., which owns and operates mobile phone manufacturing facilities in Tianjin and which is a joint-venture between the Company and Spreadtrum Technologies, Inc., is not part of the sale.

The final closing of the sale of the above-mentioned subsidiaries of the Company is anticipated to take place within the first quarter of 2013 with the exception of Profit Harvest which closing occurred as of December 31, 2012. In addition, the Company will, through Portables Unlimited, LLC, its U.S. based subsidiary, continue to operate the exclusive wholesale distributor business for T-Mobile products and services in the United States.

The Company intends to use the cash proceeds from the sale of the assets to acquire similar businesses in the U.S. to further expand its activities there, including but not limited to the acquisition of additional licensed retail stores that service T-Mobile USA.

Zoom’s Chairman & CEO, Mr. Leo Gu stated, “Our strategy is a simple one. We will focus our resources to capture revenues from U.S. based operations, which we started over a year ago by our acquisition of Portables Unlimited in New York. With this sale, our revenues will be predominantly generated from our U.S. operations. The selling of our China based operations doesn’t mean that we are out of touch with China because we can always contract with our former subsidiaries, when the need arises going forward. We feel that it is important to listen to the market which has not been favorable Chinese companies listed in the U.S., and we are confident that the combination of our continued relationships in China and the expansion of our U.S. activities is a positive direction for Zoom Technologies. We are actively seeking synergistical businesses to bring into Zoom and adding on more licensed retail stores of T-Mobile USA is a part of this plan.”

About Zoom Technologies, Inc.

Zoom Technologies is a holding Company with subsidiaries that engage in the manufacturing, research and development, and sale of electronic and telecommunication products for the latest generation of mobile phones, wireless communication circuitry and related software products. Zoom Technologies’ current subsidiary, Jiangsu Leimone, owns a majority stake of TCB Digital, which offers highly customized and high quality Electronic Manufacturing Service (EMS) for Original Equipment Manufacturer (OEM) customers as well as its Own Brand Manufacturing (OBM) under the ZOOM, LEIMONE and LONGTEL brand names. The Company’s products are both exported globally and sold domestically in People’s Republic of China. Zoom Technologies also owns a controlling interest in Portables Unlimited LLC, a cellular service and products distributor in the U.S.

The Zoom Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=9665

Forward-Looking Statements

Certain statements in this press release may constitute “forward looking statements” that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events in which the outcome cannot be assured. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.

CONTACT: Investor Contact:
         Lynn Wei
         Investor Relations Coordinator
         Zoom Technologies, Inc.
         +86-10-5935-9576
         weilin@zoom.com
         www.zoom.com

Peregrine (PPHM) Update on Phase II Lung Cancer Trial Internal Review

TUSTIN, CA — (Marketwire) — 01/07/13 — Peregrine Pharmaceuticals, Inc.(NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today provided an update from its internal review of discrepancies from its Phase II randomized, double-blind placebo-controlled trial of bavituximab in second-line non-small cell lung cancer (NSCLC) in 121 patients. The review was prompted by the discovery of vial coding discrepancies while preparing for an end of Phase II meeting with the FDA. The internal review included a thorough operational review of multiple third-party vendor operations at sites worldwide, testing of investigational product used in the trial, additional patient sample testing to determine drug levels and a review of immunogenicity testing results from the trial. The results of the extensive internal review indicate that discrepancies are isolated to the placebo and 1 mg/kg treatment arms of the trial and that there was no evidence of discrepancies in the 3 mg/kg treatment arm of the trial.

“Our goal in undertaking such a comprehensive review was to understand every aspect of this clinical trial,” said Jeffrey L. Masten, vice president, quality of Peregrine. “Due to the complex nature of this trial, this was an enormous effort involving multiple third-party vendors and thousands of product and patient samples obtained from three different continents. Specifically, we sought to determine the cause and the impact of any discrepancies within the trial and to verify every step within the drug product distribution process. We believe we have accomplished our goals in obtaining a more thorough understanding of the trial and we are very pleased with the outcome.”

Based on the results of the internal review, Peregrine is taking a very conservative approach toward analyzing the results from the trial which included combining the placebo and 1mg/kg arms into one treatment arm (control arm), and comparing those results to the 3mg/kg arm. This analysis indicates that the 3 mg/kg arm continues to show favorable tumor response rates, progression-free survival and overall survival (OS) over the new combined control arm. Peregrine expects to announce more detailed results from the analysis in the near term when it is completed.

“The results from this comprehensive review have provided a better understanding of the outcome of this trial. We believe that these results of our internal review and subsequent data analysis support advancing bavituximab into Phase III development for the treatment of second-line non-small cell lung cancer,” said Joseph S. Shan, vice president, clinical and regulatory affairs of Peregrine. “We are now preparing for discussions with the FDA and worldwide regulatory agencies.”

“With the results of this review in hand, we are now in the process of updating potential partners and moving the program forward,” said Steven W. King, president and chief executive officer of Peregrine. “Looking ahead, we anticipate data from seven ongoing bavituximab trials in different indications as well as results from an imaging study based on the same novel target.”

About Bavituximab
Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. Bavituximab is the lead drug candidate from the company’s PS technology platform and is currently being tested in eight clinical trials, including three randomized Phase II trials in front-line and second-line non-small cell lung cancer and front-line pancreatic cancer, and five investigator-sponsored trials (ISTs) in additional oncology indications. PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but “flips” and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor.

About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals’ intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the final OS data from the randomized, double-blind, placebo-controlled Phase IIb trial may be less compelling than the data as presently calculated thereby creating uncertainty with respect to the future development in second-line NSCLC, the risks that partnering discussions may not result in a partnering transaction or that such discussions could be hindered or delayed as a result of the existing class action lawsuits, the risk that results from the front-line NSCLC trail will not be consistent with results experienced in earlier trials and may not support advancing this indication into later stage trials. It is important to note that the Company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the our SEC reports including, but not limited to, the annual report on Form 10-K for the fiscal year ended April 30, 2012 and quarterly report on Form 10-Q for the quarter ended October 31, 2012. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the our SEC reports including, but not limited to, the annual report on Form 10-K for the fiscal year ended April 30, 2012 and quarterly report on Form 10-Q for the quarter ended October 31, 2012. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256

GlobalWise (GWIV) Enters New Channel Sales Partnership With Iron Data

COLUMBUS, OH — (Marketwire) — 01/07/13 — GlobalWise Investments, Inc. (OTCBB: GWIV) (OTCQB: GWIV) (www.GlobalWiseInvestments.com) and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, today announce the signing of a new channel sales partnership with Iron Data Solutions, Inc. (www.irondata.com).

Headquartered in Arlington, VA, Iron Data offers a comprehensive suite of solutions, called Intelligent Process Management, that assess, improve, manage and monitor challenging operational process issues for clients in the public sectors. Iron Data has more than 400 employees across 11 offices around the U.S. and the world, including Amsterdam, Toronto and Shenzhen, China.

“Iron Data represents another fantastic channel partner who can further expand our scope in both the public and private sector through their technological expertise and established relationships,” stated William “BJ” Santiago, CEO of GlobalWise. “Iron Data has been a proven leader in transforming how government agencies control dataflow and manage information. We are actively working to secure a large government client now and anticipate announcing a new contract with the organization soon. GlobalWise looks forward to working with Iron Data and anticipates many more client opportunities over the coming quarters.”

“We deeply value our government clients and relationships,” said Tom Gottleib, Vice President of Iron Data. “It was vitally important we found an ECM cloud-based provider who understood the mission critical and privacy needs within the government sector. GlobalWise has served these types of clients since their inception and has a rich and proven legacy to complement our reputation for implementing process management and business automation solutions that reduce waste, fraud and abuse.”

About GlobalWise Investments, Inc.

GlobalWise Investments, Inc., via its wholly owned subsidiary Intellinetics, Inc., is a Columbus, Ohio based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file or video tape — virtually anything that can be digitized — in their enterprise from any PC, laptop, tablet or smartphone from anywhere in the world.

For additional information, please visit the Company’s corporate website: www.GlobalWiseInvestments.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

GlobalWise Investments, Inc.
Columbus, Ohio
www.GlobalWiseInvestments.com
614-388-8909
Contact@GlobalWiseInvestments.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975

Alderon (AXX) to Release FeasibilityStudy, Host Conference Call on Kami Iron Ore Project

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 01/04/13 — Alderon Iron Ore Corp. (TSX:ADV)(NYSE MKT:AXX) (“Alderon”) is pleased to announce that it plans to release the results of its Feasibility Study (“FS”) on the Rose Deposit of the Kamistiatusset (“Kami”) Iron Ore Property in western Labrador prior to market open on Wednesday January 9, 2013.

Following the release of the FS, Alderon will host an analyst and shareholder conference call at 8:00am EST on the same day (January 9, 2012). To participate in the call, please dial the following:

Toronto: 416-623-0333
Montreal: 514-687-4017
Vancouver: 604-681-8564
Calgary or International: 403-532-5601                                      

Toll Free North America: 1-855-353-9183                                     

Participant Pass Code: 43764#

About Alderon

Alderon is a leading iron ore development company in Canada with offices in Vancouver, Toronto, Montreal, Labrador City and St. John’s. The 100% owned Kami Project is located within Canada’s premier iron ore district and is surrounded by four producing iron ore mines. The Alderon team is comprised of skilled professionals with significant iron ore expertise to advance Kami towards production.

For more information on Alderon, please visit our website at www.alderonironore.com.

ALDERON IRON ORE CORP.

On behalf of the Board

Mark J. Morabito, Executive Chairman

Cautionary Note Regarding Forward-Looking Information

This press release contains “forward-looking information” concerning anticipated developments and events that may occur in the future. Forward looking information contained in this press release include, but are not limited to, statements with respect to the release of the results of the Feasibility Study.

In certain cases, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” suggesting future outcomes, or other expectations, beliefs, plans, objectives, assumptions, intentions or statements about future events or performance. Forward-looking information contained in this press release is based on certain factors and assumptions regarding, among other things, the estimation of mineral reserves and resources, the realization of resource estimates, iron ore and other metal prices, the timing and amount of future exploration and development expenditures, the estimation of initial and sustaining capital requirements, the estimation of labour and operating costs, the availability of necessary financing and materials to continue to explore and develop the Kami Property (as defined herein) in the short and long-term, the progress of exploration and development activities, the receipt of necessary regulatory approvals, the completion of the environmental assessment process, the estimation of insurance coverage, and assumptions with respect to currency fluctuations, environmental risks, title disputes or claims, and other similar matters. While the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect.

Forward looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include risks inherent in the exploration and development of mineral deposits, including risks relating to changes in project parameters as plans continue to be redefined including the possibility that mining operations may not commence at the Kami Property, risks relating to variations in mineral resources, grade or recovery rates resulting from current exploration and development activities, risks relating to the ability to access rail transportation, sources of power and port facilities, risks relating to changes in iron ore prices and the worldwide demand for and supply of iron ore and related products, risks related to increased competition in the market for iron ore and related products and in the mining industry generally, risks related to current global financial conditions, uncertainties inherent in the estimation of mineral resources, access and supply risks, reliance on key personnel, operational risks inherent in the conduct of mining activities, including the risk of accidents, labour disputes, increases in capital and operating costs and the risk of delays or increased costs that might be encountered during the development process, regulatory risks, including risks relating to the acquisition of the necessary licences and permits, financing, capitalization and liquidity risks, including the risk that the financing necessary to fund the exploration and development activities at the Kami Property may not be available on satisfactory terms, or at all, risks related to disputes concerning property titles and interest, environmental risks, and the additional risks identified in the “Risk Factors” section of the Company’s Annual Information Form for the most recently completed financial year or other reports and filings applicable Canadian securities regulators. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information is made as of the date of this press release. Except as required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information.

Contacts:
Alderon Iron Ore Corp.
Montreal Office
514-281-9434
514-281-5048 (FAX)

Alderon Iron Ore Corp.
St. John’s Office
709-576-5607
709-576-7541 (FAX)

Alderon Iron Ore Corp.
Labrador City
709-944-4820
709-944-4827 (FAX)

Alderon Iron Ore Corp.
Toronto Office
416-309-2138
416-861-8165 (FAX)

Alderon Iron Ore Corp.
Vancouver Office
604-681-8030
604-681-8039 (FAX)

Alderon Iron Ore Corp.
Konstantine Tsakumis
Investor Relations
1-866-683-8030 ext. 232
info@alderonironore.com

Brower Piven Encourages Investors to Inquire About Hemispherx Biopharma (HEB) Class Action

Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Hemispherx Biopharma, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the February 22, 2013 Lead Plaintiff Deadline — HEB

STEVENSON, Md., Jan. 4, 2013 (GLOBE NEWSWIRE) — Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania on behalf of purchasers of Hemispherx Biopharma, Inc. (“Hemispherx” or the “Company”) (NYSE MKT:HEB) common stock during the period between March 19, 2012 and December 17, 2012, inclusive (the “Class Period”).

If you have suffered a net loss from investment in Hemispherx Biopharma, Inc. common stock purchased on or after March 19, 2012, and held through December 17, 2012, you may obtain additional information about this lawsuit and your ability to become a lead plaintiff by contacting Brower Piven at www.browerpiven.com, by email at hoffman@browerpiven.com, by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 60 years.

No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than February 22, 2013 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period. You are not required to have sold your shares to seek damages or to serve as a Lead Plaintiff.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period details concerning the safety and efficacy of Ampligen being developed for the treatment of Myalgic Encephalomylitis / Chronic Fatigue Syndrome.  According to the Complaint, following the FDA’s December 18, 2012 report which found the Company’s studies were ill-defined and invalid and showed inconsistent signals of efficacy and which identified nine potential safety concerns associated with Ampligen, the value of Hemispherx shares declined significantly.

If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

CONTACT: Charles J. Piven
         Brower Piven, A Professional Corporation
         Stevenson, Maryland
         410/415-6616
         hoffman@browerpiven.com